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ABSTRACT 
Karl W. Staser 
 
ERK1 AND ERK2 IN HEMATOPOIESIS, MAST CELL FUNCTION, AND THE 
MANAGEMENT OF NF1-ASSOCIATED DISEASE 
 
Neurofibromatosis type 1 is a genetic disease that results from either 
heritable or spontaneous autosomal dominant mutations in the NF1 gene, which 
encodes a protein serving, at least in part, to accelerate the intrinsic hydrolysis of 
active Ras-GTP to inactive Ras-GDP. A second-hit NF1 mutation precedes 
predominant NF1 neoplasms, including juvenile myelomoncytic leukemia (JMML) 
and plexiform neurofibroma formation, potentially fatal conditions with no medical 
therapy. While NF1 loss of heterozygosity (LOH) in myeloid progenitor cells 
sufficiently engenders leukemogenesis, plexiform neurofibroma formation 
depends on LOH in Schwann cells and Nf1 heterozygosity in the hematopoietic 
system. Specifically, recruited Nf1+/- mast cells accelerate tumorigenesis through 
secreted cytokines and growth factors. Nf1+/- mast cells depend upon 
deregulated signaling in c-kit pathways, a receptor system conserved in 
hematopoietic stem cells (HSCs). Accordingly, Nf1-/- myeloid progenitor cells, 
which can induce a JMML-like disease in mice, also demonstrate deregulated c-
kit receptor signaling. C-kit-activated Nf1+/- mast cells and Nf1-/- myeloid 
progenitors both show increased latency and potency of active Erk1 and Erk2, 
the principal cytosolic-to-nuclear effectors of canonical Ras-Raf-Mek signaling. 
v 
 Thus, Erk represents a potential regulator of leukemogenesis and tumor-
associated inflammation. However, single and combined Erk1 and Erk2 roles in 
HSC function, myelopoiesis, and mature mast cell physiology remain unknown, 
and recent hematopoietic studies relying on chemical Mek-Erk inhibitors have 
produced conflicting results. Here, we show that hematopoietic stability, 
myelopoiesis, and mast cell generation require Erk1 or Erk2, but individual 
isoforms are largely dispensable. Principally, Erk-disrupted hematopoietic stem 
cells incorporate BrdU but are incapable of dividing, a novel and cell type-specific 
Erk function. Similarly, mast cell proliferation requires Erk but cytokine production 
proceeds through other pathways, elucidating molecule-specific functions within 
the c-kit cascade. Based on these findings, we have reduced tumor mast cell 
infiltration by treating genetically-engineered tumor model mice with PD0325901, 
a preclinical Mek-Erk inhibitor. Moreover, we have devised a quadruple 
transgenic HSC transplantation model to examine dual Erk disruption in the 
context of Nf1 nullizygosity, testing whether diseased hematopoiesis requires 
Erk. These insights illuminate cell-specific Erk functions in normal and Nf1-
deficient hematopoiesis, informing the feasibility of targeting Mek-Erk in NF1-
associated disease. 
D. Wade Clapp, M.D., Chair 
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LPPC:  Low proliferation potential cell.  
MAPK: Mitogen activated protein kinase. 
M-CSF: Macrophage-colony stimulating factor. 
MCP-1: Monocyte chemotactic protein 1.  
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MIP-1a: Macrophage inflammatory protein 1 alpha. 
MIP-1b: Macrophage inflammatory protein 1 beta. 
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PEI:  Polyethyleneimines. 
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PY:  Pyronin Y. 
PVDF: Polyvinylidene fluoride. 
RANKL: Receptor activator of nuclear factor kappa-B ligand. 
RAS:  Rat Sarcoma protein. 
SCF:  Stem cell factor. 
SLAM: Signaling lymphocytic activation molecule. 
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis. 
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VEGF: Vascular endothelial growth factor. 
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INTRODUCTION 
Neurofibromatosis type 1 (NF1, von Recklinghausen’s disease) is a 
genetic disorder caused by autosomal dominant mutations in the NF1 gene, 
which encodes Neurofibromin, a protein that accelerates the hydrolysis of Ras 
from its GTP- to GDP-bound conformation. The disease afflicts approximately 1 
in 3500 persons worldwide in a pandemic fashion, and it is the most common 
genetic disorder with a predisposition to cancer (1). NF1 manifests with both non-
tumorigenic and tumorigenic maladies, including learning disabilities, skeletal 
dysplasia, non-healing fractures (pseudarthrosis), myeloid leukemia (JMML), and 
tumors such as optic glioma and the namesake neurofibroma. The disease’s 
hallmark signs include hyper-pigmented areas of the skin (café au lait macules) 
and hamartomas on the iris (Lisch nodules), which serve as important diagnostic 
criteria and may be observed in infancy or childhood of afflicted individuals (2, 3). 
Because prominent NF1 symptoms arise from neural crest-derived tissue (e.g. 
glia, Schwann cells, melanocytes), some reports have characterized NF1 as a 
disorder of the neural crest. However, NF1 pathologies arise in organs derived 
from all embryonic germ layers, and we should consider NF1 not only a tumor 
predisposition syndrome but also a systemic developmental disorder (4). 
NF1-like cutaneous tumor syndromes appeared in the literature during the 
18th century (5-7), and in the 1880s Friedrich von Recklinghausen published 
seminal observations detailing cutaneous tumors comprised of both neuronal and 
fibroblastic tissue, deeming the tumors neurofibromen (8). NF1’s pathognomonic 
neurofibromas are slowly progressing, heterogeneous solid tumors comprised of 
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Schwann cells, fibroblasts, vascular cells, and infiltrating hematopoietic cells, 
predominantly degranulating mast cells (9-14). Cutaneous and subcutaneous 
neurofibromas derive from small peripheral nerve branches during adolescence 
or adulthood and are found in nearly all individuals with NF1 (15). By 
comparison, plexiform neurofibromas afflict half or fewer individuals with NF1 and 
develop from cranial and large-peripheral nerve sheaths, possibly initiating during 
gestation or early infancy from abnormally differentiated nonmyelinating 
Schwann cells or their less-differentiated precursors (16, 17). 
Plexiform neurofibromas are typically a lifelong source of disfigurement, 
disability, and mortality. In many cases, plexiform neurofibromas compress 
cranial nerves and/or peripheral nerve roots at the vertebral column and create 
an array of morbidity, including paresthesia, paralysis, drooling, sleeplessness, 
respiratory and gastrointestinal distress, blindness, and loss of bowel and 
bladder control (18, 19). A plexiform neurofibroma also has the potential to 
transform into a malignant peripheral nerve sheath tumor (MPNST), a highly 
morbid, metastatic cancer afflicting up to 10% of NF1 patients in their lifetime (20, 
21).  
Plexiform neurofibroma treatment consists primarily of symptom 
management and/or surgical resection. In many cases, the tumor’s close 
involvement with vital nerve tissue, vasculature, or other viscera complicates 
surgery (18, 19, 22). Currently, the tumors have no medical therapy or cure, 
although several molecularly-targeted compounds are in preclinical or clinical 
testing (23-27). Problematically, nerve sheaths and heavily collagenized areas 
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may resist drug bioavailability, complicating direct pharmacological inhibition of 
the tumorous mass. Therefore, therapeutic strategies targeting components of 
the tumor microenvironment, including vascular cells and infiltrating mast cells, 
may prove viable alternatives (28). 
Mast Cells, Tumors, and the NF1 Hematopoietic System 
Mast cells are granular hematopoietic cells that arise from myeloid 
progenitor cells prior to granulocyte/monocyte lineage commitment (29). Mast 
cell precursors migrate from the bone marrow into the vasculature and enter 
dermal tissue where they mature into immune effector cells. Mast cells fight 
pathogens, protect against venoms and toxins, and may perform other 
immunomodulatory functions, both pro- and anti-inflammatory (30-33). While 
mast cells are predominantly known as the mediators of allergy and allergic 
asthma via IgE/FcεR pathways, they additionally depend on stem cell factor 
(SCF) signaling at the c-kit receptor tyrosine kinase for their generation and, in 
some contexts, pathophysiological activation (34-37). Indeed, mice naturally 
mutated at the c-kit receptor tyrosine kinase (W, or “white spotting locus” 
mutants, which reduces c-kit kinase activity >85%) exhibit profoundly reduced 
numbers of tissue-resident mast cells (35). Some W mice have anemia and 
deficient hematopoiesis, as the hematopoietic stem cell (HSC) also depends 
upon SCF/c-kit signaling. 
 The pro-inflammatory activities of recruited mast cells and other immune 
effector cells have been shown to sustain tumor microenvironments in various 
disease models (reviewed in (38-40)). In this inflammatory microenvironment 
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hypothesis, tumorigenic cells recruit and co-opt the functions of non-tumorigenic 
hematopoietic cells via unchecked mitogenic and chemotactic signals. These 
recruited cells, in turn, coordinate vascular in-growth, collagen deposition, and 
the pathological inflammation promoting extracellular matrix remodeling, tumor 
expansion, invasion, and metastasis. Specifically, mast cells can synthesize and 
secrete matrix metalloproteinases (MMPs), various cytokines (e.g. IL-6 and TNF-
α), and multiple mitogens (e.g. NGF, VEGF, and PDGF) (32, 33) with putative 
roles in tumor initiation, maintenance, and growth. 
Mast cells have been associated with NF1 since 1911, when H. Greggio 
first noted les cellules granuleuses in neurofibroma tissue (14). Decades later, 
several investigators confirmed their presence using traditional histology and 
electron microscopy (9-13). By the 1980s, mast cells were widely-recognized 
inflammatory effectors and hallmark histological features (albeit of unknown 
significance) of the neurofibroma. Vincent Riccardi first hypothesized that mast 
cells may critically contribute to neurofibroma formation, proposing that mast cell 
degranulation explained his clinical observations of coincident pruritus and 
cutaneous neurofibroma formation (41). Indeed, a small human study with a mast 
cell granule stabilizer (ketotifen) reduced pruritus and/or slowed neurofibroma 
growth (42), but a subsequent multiphase trial confirmed only anti-pruritic and 
analgesic effects, not neurofibroma reduction (43). These inquiries provided 
important evidence of aberrant mast cell degranulatory activity in neurofibroma 
tissue yet suggested that local inhibition of degranulation alone does not change 
overall disease course. As discussed in this review, recent biochemical, 
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transplantation, and pharmacological studies have implicated a preponderant 
role for SCF-mediated mast cell gain-in-functions in orchestrating the 
neurofibroma microenvironment. This SCF-mediated coordination of mast cell 
inflammation and tumor growth may inform a novel approach to NF1 
therapeutics. 
Intriguingly, the mast cell shares functional and phenotypic similarities with 
hematopoietic stem and progenitor cells, potentially informing mechanisms of the 
coincident occurrence of JMML in NF1 patients. This myelomonocytic neoplasia, 
which has no therapy or cure and is uniformly fatal, results from loss of NF1 
heterozygosity in hematopoietic stem and progenitor cells, which become 
hypersensitive to multiple cytokines, including GM-CSF and SCF (44, 45). Like 
mast cells, all hematopoietic stem and progenitor cells express the c-kit receptor 
tyrosine kinase and utilize SCF signaling for their proliferation, differentiation, and 
survival (46). Thus, we can consider the NF1 hematopoietic system to be one of 
myeloid dysfunction at the level of hematopoietic stem and progenitor cells, 
including mast cell precursor cells (Figure 1).
F 
igure 1 
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Figure 1: Myeloid hierarchy with an emphasis on cells known to be 
dependent on Neurofibromin signaling. The hematopoietic stem cell (HSC) 
gives rise to multipotent progenitors (MPP), which can differentiate to the 
common myeloid progenitor (CMP) or the common lymphoid progenitor (not 
shown). The CMP gives rise to granulocyte-macrophage progenitors (GMP), 
mast cell precursors, and erythroid lineages (not shown). The GMP, in turn, gives 
rise to the granulocyte progenitor (GP) and the macrophage/monocyte progenitor 
(MP), which can differentiate into multiple cell types, including macrophages, 
osteoclasts, and dendritic cells. The shaded box indicates lineages known to be 
hyper-responsive to the indicated cytokines, subsequent to mono- or biallelic 
inactivation of Nf1/NF1. SCF: stem cell factor, Flt3L: Flt3 (fms-like receptor 
tyrosine kinase 3) ligand, Il-3: interleukin-3, GM-CSF: granulocyte-macrophage 
colony stimulating factor, M-CSF: macrophage colony stimulating factor, G-CSF: 
granulocyte colony stimulating factor.  
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NF1 Genetics 
A century after von Recklinghausen’s seminal case reports, genetic 
linkage studies in NF1-afflicted families identified the pericentromeric region of 
chromosome 17 as the genomic region harboring the gene responsible for the 
disease (47, 48). Further studies in patients with translocations of chromosome 
17 (49-52) facilitated the identification and full-length sequencing of the NF1 
gene (53), which spans 350 kilobases of human chromosome 17 (17q11.2) and 
encodes 59 exons producing a 2818 amino acid protein (49, 54-56). Of note, 
human Neurofibromin and its mouse homolog share 98% identity at the protein 
level (57). 
Approximately half of NF1 mutations in humans arise spontaneously (58), 
with the majority of mutations leading to premature truncation of the protein 
neurofibromin (59, 60). When NF1 mutations occur post-meiotically, individuals 
may exhibit segmental NF1 with manifestations confined regionally or to a subset 
of normally affected cell types (e.g. only pigmentation defects) (61). Different NF1 
frameshift and point mutations do not necessarily correlate with phenotypic 
severity, although some studies have shown that microdeletions encompassing 
the entire NF1 locus (which account for less than 10% of mutations) associate 
with earlier onset and more profound disease manifestations (62, 63). Phenotypic 
variation tends to be high even within families, and pedigree analyses indicate 
that while NF1 mutations are fully penetrant, variation in genes independent of 
the NF1 locus critically modulates time-to-onset and course of the disease (64, 
65). Parallel to the human data, different Nf1-mutant mouse strains exhibit both 
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varied expression levels of neurofibromin and variable susceptibility to different 
NF1-like disease manifestations (66). Overall, with the exception of the 
documented severity associated with NF1 locus-encompassing microdeletions 
and a uniquely mild phenotype associated with a 3-base pair deletion in exon 17 
(67), particular genetic mutations or genomic variations which may correlate to 
specific disease outcomes are largely unknown.  
NF1 encodes neurofibromin, a protein which functions, at least in part, as 
a p21ras (Ras) guanosine tri-phosphatase (GTP) activating protein (GAP) (68-72). 
Neurofibromin and other Ras-GAPs logarithmically accelerate the intrinsic 
hydrolysis of Ras-GTP to its inactive guanosine di-phosphate- (GDP)-bound 
conformation (73). In response to multiple mitogenic stimuli, active Ras-GTP 
orchestrates diverse protein signaling networks, including mitogen activated 
protein kinase- (MAPK)- and Akt-directed pathways (74-78). Hence, by 
accelerating the conversion of Ras-GTP to Ras-GDP, neurofibromin negatively 
regulates Ras-dependent signaling cascades and, generally, serves to 
downregulate mitogenic events across diverse protein networks. In cases of NF1 
heterozygosity or nullizygosity, as observed in somatic cells and in tumor cells of 
individuals with NF1, respectively, downstream Ras-mediated phosphorylation 
and transcriptional events can increase in duration and total output. This global 
upregulation of Ras-dependent activity in NF1/Nf1-disrupted tissue typically leads 
to cellular gain-in-functions, including enhanced proliferation, migration, and 
survival in multiple cell types (reviewed in (79-83). Of note, the specific Ras 
effectors potentiated by loss of NF1 may vary by cell and receptor type, and 
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biochemical consequences in one cell-receptor system may or may not be 
observed in another.  
Nf1 Gene Dosage 
Although NF1 is classified as a classical Knudson tumor suppressor gene, 
multiple studies have shown that NF1 heterozygosity critically modulates cell fate 
and function by altering Ras-dependent biochemical pathways in distinct cell 
types (reviewed in (82)). Moreover, physiological Ras activity regulates 
embryogenesis, early development, and normal tissue maintenance. Therefore, 
neurofibromin may be viewed not only as a tumor suppressor but also as a 
regulator of histiogenesis, cellular maintenance, and repair (4). Accordingly, NF1 
is a disorder of both tumor predisposition and of developmental dysplasia. 
While somatic cells in an individual with NF1 are heterozygous for NF1, 
loss of heterozygosity (LOH) in different cell types typically precedes hallmark 
hyperplastic, dysplastic, and neoplastic disease manifestations. LOH has been 
shown in human tissue samples and confirmed in NF1 mouse models of certain 
NF1 pathologies via multiple molecular techniques, coinciding with NF1’s 
designation as a classical tumor suppressor gene. As examples, LOH in 
Schwann cells or their precursors permits neurofibroma formation (17, 84-86) 
and LOH in myeloid progenitor cells induces myelomonocytic leukemia (44).  
Individuals with NF1 also have an increased prevalence of multiple 
generalized manifestations which do not appear to require cell-specific biallelic 
inactivation of NF1, including skeletal and mesenchymal dysplasia (e.g. short 
stature, osteoporosis, and soft tissue malformation), disorders of neurocognitive 
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development (e.g. retardation, spatial/visual coordination, and autism), and 
vascular pathologies (e.g. fistulae, infarcts, and aneurysms). Hence, NF1 
heterozygosity alone alters Ras-dependent pathways to a degree sufficient for 
the pathological alteration of normal developmental and homeostatic processes 
in multiple organ systems.  
Indeed, Nf1 haploinsufficient mast cells and fibroblasts, major constituents 
of the heterogeneous plexiform neurofibroma, demonstrate multiple gain-in-
function phenotypes that include enhanced proliferation, survival, migration, and 
cytokine production in response to specific stimuli (87, 88). These data parallel 
findings in Nf1 haploinsufficient microglia (89), which critically modulate the 
inflammatory microenvironment of NF1-associated optic glioma (90-92).  
In some mouse models of plexiform neurofibroma and optic glioma 
formation, tumorigenesis requires Nf1 haploinsufficiency in non-tumorigenic cells. 
Specifically, hematopoietic stem cell transplantation studies in the Nf1flox/flox; 
Krox20°Cre and Nf1flox/flox; P0aCre models (which experience biallelic Nf1 
inactivation in a subset of Schwann cell/Schwann cell precursors) have shown 
that neurofibroma genesis requires Nf1 haploinsufficiency and c-kit-mediated 
signaling in the hematopoietic compartment (24). In these experiments, Nf1flox/flox; 
Krox20°Cre mice required Nf1+/- hematopoietic stem cell transplants to engender 
tumorigenesis, while WT hematopoietic stem cell transplants protected against 
tumorigenesis in Nf1flox/-;Krox20°Cre mice. These data, combined with cell culture 
studies of Nf1+/- mast cells, roundly implicate the Nf1 haploinsufficient 
hematopoietic compartment (and, specifically, deregulated myeloid and mast 
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cells), as a principal pathologic component of the plexiform neurofibroma 
microenvironment.  
By comparison, clonal outgrowth in NF1-associated JMML depends on 
Nf1/NF1 LOH in hematopoietic stem and progenitor cells (c-kit+ cells) with no 
requirement for an Nf1+/- cellular background. As evidence, transplantation of 
Nf1-/- hematopoietic stem cells into WT mice engenders a myeloproliferative 
disorder (MPD) recapitulating human JMML (44, 45, 93). However, in human 
cases of NF1-associated JMML, we expect all surrounding somatic cells in the 
individual to be essentially NF1+/-. Of note, no report has directly investigated 
possible contributions of an Nf1+/- stroma to the time-to-onset, progression, and 
severity of NF1-associated MPD.  
Mek-Erk Signaling in Mast Cells 
SCF regulates mast cell and hematopoietic progenitor cell cytopoiesis, 
proliferation, survival, and cytokine synthesis, and Nf1 deficiency can potentiate 
these functions. In fact, the study of SCF-stimulated Nf1+/- mast cells provided 
foundational evidence that haploinsufficiency of a “tumor suppressor” could 
modulate multi-lineage cell fate and function in tissue culture and in vivo (87). 
This study additionally demonstrated that Nf1 haploinsufficiency increases the 
latency and potency of GTP-bound Ras in SCF-stimulated cells. Subsequent 
studies have detailed the biochemical mechanisms modulating SCF-mediated 
gain-in-functions, showing alterations arising from deregulated signaling events 
in multiple Ras-dependent networks. In response to ligand binding at diverse cell 
surface receptors, Ras activates to its GTP-bound state and promotes 
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phosphorylation in downstream protein networks, including those orchestrated by 
MAPKs and phosphoinositide-3-kinase (PI-3K) (75-78). Neurofibromin, which 
contains a highly-conserved GAP-related domain (GRD) with homology to the 
yeast gene products IRA1 and IRA2, logarithmically accelerates the intrinsic 
hydrolysis of active GTP-bound Ras to its GDP-bound state (50, 55, 68, 71, 79, 
94). Generally, loss-of-function mutations in genes encoding Ras-GAPs promote 
cell growth, proliferation, migration, and survival (40). In myeloid progenitor cells, 
microglia, and mast cells, loss of one or both alleles of Nf1 leads to increased 
duration of Ras-GTP activity and phosphorylation of specific effectors within Raf-
Mek-Erk, PI-3K-Rac-Pak-P38, and PI-3K-Akt cascades (44, 45, 87, 92, 95-100). 
Cell culture and in vivo studies of genetically-disrupted mast cells indicate 
that the Raf-Mek-Erk pathway may primarily modulate SCF-mediated 
proliferation and protein synthesis while the PI-3K-Rac2-Pak-p38 pathway 
controls F-actin dynamics and cellular motility (97, 98, 100-103). Biochemical 
investigations have additionally shown that the PI-3K-dependent pathway 
reinforces the classical Raf-Mek-Erk cascade through the activity of the p21 
activated kinases (Paks) (98, 102). In this schema, PI-3K-activated Rac2 induces 
Pak1 to phosphorylate Mek at serine 298 as well as Raf1 at serine 338, 
potentiating Raf1’s phosphorylation of Mek at serine 217/222. These activities 
potentiate phosphorylation of the extracellular regulated kinases, Erk1 and Erk2. 
Erk1 and Erk2 phosphorylate cytoplasmic targets (e.g. p90rsk), translocate to the 
nucleus, and activate multiple mitogenic transcription factors (e.g. c-Fos, Elk1, 
C/EBP). 
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However, direct genetic studies of Mek-Erk signaling in the SCF-
stimulated mast cell are lacking. All prior investigations have relied on chemical 
inhibitors of Mek (e.g. PD98059), which are known to have non-selective 
inhibitions and cellular toxicities. Moreover, Erk1 and Erk2’s specific modulation 
of the mast cell cycle, as well as Erk-dependent transcriptional events, including 
the production of inflammatory cytokines, are not documented. Finally, it is 
unknown whether Erk1 and Erk2 have isoform specific roles in the modulation of 
SCF-mediated mast cell function (Figure 2).  
Figure 2 
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Figure 2: Hyperactive SCF:c-kit pathways in the Nf1+/- mast cell. Kit-ligand 
(SCF) binding at the c-kit receptor tyrosine kinase induces receptor dimerization, 
activates Ras to its GTP-bound conformation, and induces Ras-Raf-Mek-Erk and 
PI-3K-Rac-Pak-p38 signaling pathways. While Mek-Erk signals may principally 
mediate mast cell proliferation, PI-3K activation mediates survival, motility and, 
through its Pak-dependent crosstalk with Raf-Mek, proliferation. Neurofibromin 
accelerates the intrinsic hydrolysis of Ras-GTP to inactive Ras-GDP and serves, 
at least in part, to negatively regulate Mek-Erk- and PI-3K-directed pathways. 
Although SCF-c-kit interactions initiate other molecular events, this schematic 
highlights only those thus far shown to be hyperactive in the Nf1+/- mast cell. 
Dashed lines indicate multiple downstream effectors not fully detailed.  
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Mek-Erk Signaling in Hematopoietic Stem and Progenitor Cells 
Like the SCF-stimulated Nf1+/- mast cell, Nf1-/- myeloid progenitor cells (c-
kit+) stimulated with various combinations of SCF, IL-3, and GM-CSF show 
increased potency and latency of phospho-Erk1/2. This finding corresponds to 
increased proliferation, colony formation, and the ability of these cells to initiate a 
JMML-like disease in mice (44, 45). These three cytokines are critical to the 
proliferation and differentiation of hematopoietic stem cells (HSCs), multipotent 
progenitor (MPPs), and myeloid progenitors (MPs), and they induce the 
phosphorylation of Erk1 and Erk2 in both normal and Nf1-deficient signaling 
contexts. 
However, genetic hematopoietic studies of single and dual Erk1 and Erk2 
disruption have focused on only T and B lymphocytes (104, 105). Of note, 
myelopoietic studies relying on Mek-Erk chemical inhibitors in tissue culture have 
produced seemingly contradictory results (106-108). In the single previous 
assessment of dual Erk1/2 disruption in hematopoietic stem cells (Mx1Cre+Erk1-/- 
Erk2flox/flox), Yasuda et al reported defects in pre-B cell expansion (105). They did 
not examine myelopoiesis, long-term hematopoiesis, or HSC proliferation. 
Moreover, recent hematopoietic studies using Mek-Erk chemical inhibitors in 
tissue culture have reached conflicting conclusions (reviewed in (109)), 
suggesting contrasting effects of chemical Mek-Erk inhibition on monocyte, 
granulocyte, and myeloid progenitor differentiation (106-108, 110). These studies 
reinforce the notion that data derived from chemical inhibitors in tissue culture 
may not accurately represent in vivo physiology. Therefore, genetic in vivo data 
18 
are needed to elucidate Erk1 and Erk2’s importance (or dispensability) in HSC 
proliferation, myelopoiesis, and mature effector cell (e.g. mast cell) function.  
Global Observations on the Functions of Erk1 and Erk2 
Globally, Erk1 and Erk2, 44 and 42 kDa proline-directed protein kinases 
which share about 83% homology at the amino acid level, appear to ramify 
critical signals across diverse cell types and ligand-receptor systems (111). 
Indeed, many tissue culture-based studies have broadly implicated Erk1 and 
Erk2 kinase activity in the control of cell differentiation, proliferation, survival, 
motility, and protein synthesis. Generally, ligand binding at cell surface receptors 
induces Mek1/2 to phosphorylate Erk1 and Erk2, which phosphorylate a number 
of cytoplasmic targets before translocating to the nucleus to phosphorylate 
mitogenic transcription factors. Of note, the Raf-Mek-Erk cascade is increasingly 
being targeted in preclinical and clinical trials of novel, small molecule anti-cancer 
drugs (112), and the recently developed Mek-Erk inhibitor PD0325901 
demonstrates high selectivity, potency (IC50 at nanomolar to sub-nanomolar 
concentrations), and low toxicity (113). Thus, the clinical application of Mek-Erk 
inhibition in disease management verges on the immediate horizon. 
Of concern, though, many of the mechanistic and functional conclusions 
regarding Erk1 and Erk2 derive either from the use of older generation Mek 
inhibitors (e.g. PD98059, U0126) or from dominant-negative overexpression in 
cell lines. While these multitudinous studies have vastly delineated Erk1 and 
Erk2’s importance in various cell functions, amalgamations of these cell culture 
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studies have created potentially erroneous cell-type specific conclusions for Erk1 
and Erk2 roles in vivo. 
 For example, many cell culture studies have shown that Erk1 and Erk2 
kinase activity, via transcription factors such as c-Fos and c-Jun, regulates the 
G1/S transition, leading to a broad conclusion that Erk1 and Erk2 globally control 
DNA synthesis (i.e. “the master regulator of G1/S”) but not later cell cycle 
progression (114). However, a recent genetic in vivo study found that even 
though Erk1/2 regulates G1/S in fibroblasts, the kinases appear to specifically 
influence G2/M in keratinocytes (115), indicating lineage-specificity of Erk’s 
proliferative control. Of note, many tissue culture-based studies of Mek-Erk 
function have relied on NIH 3T3 or mouse embryonic fibroblasts, both of which 
have a fibroblastic origin. Intriguingly, lineage-specific study in primary embryonic 
stem cells found that Erk1/2 activity controls cellular differentiation but not 
proliferation (116), and, using these insights, investigators are applying 
PD0325901 to embryonic and induced pluripotent stem cells to encourage their 
self-renewal ex vivo (117-119). Taken together, these findings raise the 
possibility that Erk1/2 activity is dispensable for DNA synthesis and/or 
proliferation in certain cell types (including hematopoietic stem cells, progenitor 
cells, and mast cells) while highlighting the importance of genetic in vivo studies 
restricted to specific cell lineages. Cell-specific insights hold a practical 
relevance, as demonstrated by embryonic stem cell research, where delineation 
of Erk function has endowed an unexpected usefulness for chemical Mek-Erk 
inhibition. 
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The generation of an Erk1 knockout mouse (Erk1-/-) (120) and, more 
recently, an Erk2 conditional knockout mouse (Erk2flox/flox) (121, 122) have 
permitted delineation of singular and combined functions of Erk1 and Erk2. 
Interestingly, isoform specific roles have emerged in some cell types but not 
others (123). Erk1 disruption enhances striatal-dependent learning (124), 
susceptibility to cocaine addiction (125), hepatocyte survival (126) but not 
proliferation (127), and the proliferative capacity of fibroblasts (128) while 
suppressing adipogenesis (129). In the hematopoietic system, Erk1 disruption 
alters thymocyte differentiation (120), favors Th1 cell polarization (130), and 
increases splenic erythropoiesis (131). In some studies, Erk1 disruption 
potentiates Mek-Erk2 signaling, suggesting a mechanism for unexpected gain-in-
functions (124, 125, 128). However, genetic studies in fibroblasts have shown 
both isoforms to positively contribute to proliferation, in a gene dose-dependent 
and isoform-independent manner (132, 133). Enhanced proliferation in some 
Erk1-disrupted cells, then, may result solely from Erk2 over-compensation (i.e. 
not from intrinsic negative-regulator properties). 
Accordingly, Erk2 disruption principally suppresses cell function, including 
embryonic lethality at E11.5 due to failed placental vascularization (121). In 
hepatocytes, Erk2 disruption reduces proliferative capacity (127), an observation 
reproduced in vitro and in vivo with normal and transformed fibroblasts (128). 
Similarly, Erk2 excision in neurons reduces cognitive function (122), including 
impaired long-term memory (134). In humans, ERK2 mutations correlate with 
cognitive deficits, developmental delays, microcephaly, and cardiac outflow tract 
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abnormalities, all of which are symptoms of DiGeorge syndrome, a chromosome 
microdeletion disease which can affect ERK2’s locus on chromosome 22 (135, 
136). Based on current publications, then, Erk2 may be viewed as the 
preponderant operator among the two kinases. However, this supposition needs 
genetic validation in specific cell lineages, and several in vivo studies have found 
no detectable phenotypic consequence of singular Erk1 or Erk2 disruption. 
Notwithstanding, the potential for isoform-specific roles for Erk1 and Erk2 
in specific cell lineages holds a particular medical relevance. A recent crystal 
structure of human ERK1 revealed substantial differences in D-motif and 
backside binding sites, as compared to ERK2, indicating the feasibility of 
selective ERK1 or ERK2 inhibitory agents (137). Given the suspected critical 
contribution of combined ERK1/2 signaling to multiple cell types, singular ERK1 
or ERK2 inhibition may engender highly-selective targeting of aberrant biological 
activity in diseased cells while avoiding systemic toxicities.  
Indeed, in the few organ systems thus far examined, dual Erk1/2 
disruption leads to profound diminution of cell function, including critical 
regulation of endothelial cell proliferation and migration (138), luteinizing 
hormone-induced female fertility from the normal maintenance of granulosa cells 
(139), radial gliomagenesis and cortical lamination (140), and osteoblast 
differentiation (141). With the exception of the neuronal studies, the authors 
observed mild, if any, effects of singular Erk disruption. 
Given these previous studies, Erk1 and Erk2 may differentially, 
reciprocally, or inconsequentially influence normal and diseased hematopoiesis 
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and SCF-mediated mast cell function. Finally, given plethoric studies of Erk1/2 
signaling suggesting broad and diverse roles for the molecules, the putative 
consequences of Erk disruption in hematopoietic cells may hinge on altered 
proliferation, differentiation, survival, and/or protein synthesis. 
THESIS OVERVIEW 
NF1 deficiency induces increased latency and potency of Erk1 and Erk2 
phosphorylation in SCF-stimulated mast and myeloid progenitor cells. NF1 
deficiency and hyper-phosphorylated effectors in c-kit-regulated pathways 
correlate with abnormally increased proliferation, survival, and protein synthesis. 
Accordingly, Erk1 and/or Erk2 could be feasible targets for the medical 
management of plexiform neurofibromas and NF1-associated JMML, especially 
given the recent development of the pharmacological grade Mek-Erk inhibitor 
PD0325901. However, foundational genetic studies regarding Erk1 and Erk2’s 
singular and/or combined functions in hematopoietic stem cell and mast cell 
function are lacking. Here, we use genetic approaches to disrupt Erk1, Erk2, and 
Erk1/2 in hematopoietic stem cells, assessing the functional consequences on 
myelopoiesis and global hematopoiesis. We then assess the consequence of 
Erk1, Erk2, and Erk1/2 disruption in SCF-stimulated mast cells in tissue culture 
while examining the efficacy of systemic PD0325901 administration in treating 
mast cell invasion and plexiform neurofibroma maintenance in a mouse tumor 
model. We additionally describe an ongoing, long-term experiment to test genetic 
Erk1/2 disruption in the context of Nf1-dependent leukemia.  
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MATERIALS AND METHODS 
Mice, Genotyping, and Mx1Cre Induction 
Previously described Erk1-/- (120) and Erk2flox//flox (104) mice were bred 
with Mx1Cre transgenic mice and each other. Genotyping was performed as 
described previously (104, 120, 142). Cre expression was induced in age/sex-
matched cohorts by seven intraperitoneal injections of poly I poly C (polyIC, 
Sigma) dissolved in sterile PBS, using a 27-gauge 0.5” inch needle inserted into 
the left peritoneal cavity just above the inguinal ligament. To minimize toxicity at 
initial doses, we used a graded dosing scheme, starting at 15 μg/g body weight 
and ending at 25 μg/g on the seventh dose. Mice were weighed periodically 
throughout the dosing regimen, and the average dose throughout amounted to 
~20-22 μg/g body weight. Transplanted mice received 6 doses of polyIC, graded 
between 10 and 20 μg/g body weight (average dose, ~15-17.5 μg/g body 
weight).  
PolyIC is a synthetic dsRNA which induces cells to produce and release 
IFN-β, driving transcription via JAK-STAT signals at the Mx1 gene promoter and 
thus inducing Cre expression in Mx1Cre transgenic mice. Previous studies have 
demonstrated that Mx1Cre potently expresses in hematopoietic stem and 
progenitor cells subsequent to polyIC administration (143, 144). All mice in an 
experiment received identical doses of polyIC throughout, based on body weight, 
regardless of genotype. Mice were maintained at Indiana University School of 
Medicine according to the Institutional Animal Care and Use Committee and 
Institutional Review Board guidelines. 
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Marrow Isolation 
After Cre induction, femoral, tibial, and/or iliac bone marrow was flushed in 
Iscove’s Modified Dulbecco’s Media (IMDM, Gibco/Invitrogen), supplemented 
with 0.5-1.0% bovine serum albumin (BSA, Sigma) or 2% fetal bovine serum 
(FBS, Hyclone, ThermoScientific) using a 23-gauge 1.5” inch needle. In 
quantitative studies, all femurs received the same number of flushes with the 
same quantity of media. Low density mononuclear cells were isolated by density 
gradient (Histopaque, Sigma), as described (45). Briefly, harvested cells were 
carefully layered onto an equivalent volume of Histopaque and centrifuged for 20 
minutes at 2000 rpm on a gh-3.8 rotor (Beckman Coulter). Cells were washed in 
IMDM or other media, as appropriate, before beginning enumeration, colony 
assays, or flow cytometry-based experiments. Enumeration was performed by 
hemcytometer and trypan blue exclusion, with three replicates counted and 
averaged per biologically-independent sample.  
Colony Assays 
Methylcellulose-based colony forming unit assays and LPPC-HPPC 
assays were performed as described (45, 145). For LPPC-HPPC, 25,000 low-
density mononuclear cells were mixed in 0.33% agar and placed on solidified 1% 
agar containing 20% FBS, 100 ng/mL SCF, 10 ng/mL GM-CSF, 5 ng/mL IL-3, 10 
ng/mL M-CSF, 10 ng/mL G-CSF (Peprotech), and 4U/mL EPO (Amgen). Colony 
plates were then placed at low oxygen (5%) and 5% CO2/37°C. Colonies were 
enumerated by inverted light microscope after one week (LPPC) and two weeks 
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(HPPC), with HPPCs described as a densely-cored colony covering at least 
three-quarters of a 2 mm2 area on a 35 mm2 Nunclon gridded plate (Thermo 
Scientific).  
For the methylcellulose-based protocol, 25,000 low density mononuclear 
cells were mixed in 1 mL 1% methylcellulose (Stem Cell Technologies) enriched 
with 30% FBS, 10-4 M β-Mercaptoethanol, and the cytokines/concentrations as 
listed above (LPPC-HPPC), or as listed for individual experiments, and then 
plated in duplicate or triplicate on 35 mm2 Nunclon gridded plate using a16-
gauge 1.5” inch needle. After one week growth in room oxygen and 5% 
CO2/37°C, colonies were enumerated by inverted light microscope, with a colony 
defined as an aggregation of at least 50 bone marrow cells originating from a 
central point.  
Single Cell Colony Assays 
For single-cell colony assays, freshly-isolated low-density marrow cells 
were stained with fluorophore-conjugated antibodies to HSC-defining cell surface 
proteins (see below) and sorted by FACS (FACSAria, BD) into a 96-well flat 
bottom plate containing 100 μL of 1% methylcellulose enriched with 30% FBS, 
100 ng/mL SCF, 10 ng/mL IL-3, 10 ng/mL Flt3-ligand, and 4 U/mL EPO and 
allowed to grow for seven to ten days in 5% CO2/37°C. After enumeration of 
large colonies (>50 cells), each well was then fixed in 4% PFA, washed twice 
with PBS, and resuspended in 4',6-diamidino-2-phenylindole (DAPI, Invitrogen) 
containing PBS, allowing efficient visualization of low cell numbers. The ability of 
the FACSAria to accurately perform single-cell plating is regularly evaluated by 
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members of the Indiana University School of Medicine Flow Cytometry Core by 
spotting individual events on glass slides. 
Bone Marrow Histology 
For histological analyses, we placed the right femur of age/sex-matched 
mice in a phosphate-buffered 10% formalin solution immediately after killing and 
fixed for up to two weeks. Femurs were then decalcified in 
Ethylenediaminetetraacetic acid (EDTA), embedded in paraffin, and cut into 8 μm 
sections by our in-laboratory histology core. Tissue sections were mounted onto 
glass slides and stained with H&E or Masson’s tri-chrome using standard 
histological techniques. 
Hematopoietic Stem Cell Transplantation 
For competitive transplantation assays, bone marrow cells were first 
isolated, as described above, from CD45.2+ Erk mutant and CD45.1+ WT BoyJ 
mice, which were obtained from the Indiana University School of Medicine In 
Vivo Therapeutics Core. Viable bone marrow cells were counted by 
hemcytometer with Trypan blue exclusion and standardized by concentration in 
PBS. Erk mutant and WT cells were then mixed, at ratios indicated in individual 
experiments, and injected with a 27 gauge 0.5” needle into the lateral tail vein of 
lethally-irradiated (1100 cGy, split dose, cesium isotope source) CD45.1/2+ WT 
mice, which were obtained from the Indiana University School of Medicine In 
Vivo Therapeutics Core. In all experiments, each mouse received 2x106 total low 
density bone marrow cells suspended in 200 μL PBS. Mice were housed in a 
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pathogen-minimized room. Mice were considered long-term reconstituted four 
months post-transplantation. 
Peripheral Blood Isolation 
At the indicated times after transplantation and before/after polyIC 
injection, 50-100 μL of blood was extracted from the lateral tail vein of transplant 
recipients via a superficial excision, perpendicular to the vein, created by a 
disposable feather scalpel. Blood was collected in a microcapillary tube (Kimble 
Kimax), transferred to an EDTA coated tube (BD Biosciences), mixed well to 
avoid clotting, and transferred to a 5 mL flow cytometry tube (BD Biosciences) 
containing 2 mL of RBC lysis buffer (Qiagen). Whole blood was incubated in this 
lysis buffer for 10 to 15 minutes at room temperature then washed twice with 
PBS. After washing, cells were resuspended in 100 μL of 3% FBS/0.09% NaN3 in 
PBS (“flow buffer”) and kept on ice for further treatment prior to analysis by flow 
cytometry.  
Secondary Transplantation 
Erk mutant and CD45.1+ WT BoyJ marrow cells were mixed at a 19:1 ratio 
and injected I.V. into lethally-irradiated (1100 cGy, split dose) CD45.1/2+ WT 
mice (total of 2x106 bone marrow cells in 200 μL PBS), as described in the 
“Hematopoietic Stem Cell Transplantation” section. After four months, primary 
transplant recipients were injected with a six-dose regimen of polyIC, allowed 
one month recovery, then one mice from each cohort killed to extract bone 
marrow for analysis and secondary transplantation. Secondary transplantation 
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was performed in a non-competitive fashion by injection of 2.0x106 bone marrow 
cells suspended in 200 μL PBS into lethally-irradiated (1100 cGy, split dose) 
CD45.1/2+ WT recipients. Secondary transplant recipients were housed in the 
same pathogen-minimized room as the primary recipients. Peripheral blood was 
isolated and analyzed as described above. 
Flow Cytometry 
Acquisition: For both isolated peripheral white blood cells and bone 
marrow cells, cells were incubated at 4°C for 30 to 60 minutes with saturating 
concentrations of anti-mouse antibodies in flow buffer supplemented with 0.25 μg 
Anti-mouse CD16/CD32 (“Fc Block”). Data were acquired on a BD FACSCalibur 
or a BD LSR II 407 flow cytometer outfitted with red (633 nm, 2 detectors), blue 
(488 nm, 5 detectors), and violet lasers (407 nm, 2 detectors) using FACSDiva 
software (BD). For most experiments, single color compensation controls were 
obtained using 1-to-2 drops of polystyrene microbeads (BD Biosciences) treated 
with each experimental fluorophore-conjugated antibody and suspended in 400 
μL PBS.  
Analysis: Compensation matrices were calculated using a defined 
algorithm in FlowJo 7.6.3 software (TreeStar), with the single-color data acquired 
from fluorophore-conjugated antibody-stained polystyrene microbeads. 
Compensation parameters were then applied to all samples. Initial gates were 
set using characteristic forward and side scatter parameters. Further gating was 
typically determined using fluorescence minus-one controls. Gates were set on a 
single sample in a blinded fashion and then automatically applied to all samples. 
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Quantitative data were assembled by batch export of gated values. Statistical 
analyses were performed as described below.  
Flow Cytometry Antibodies 
All flow cytometry fluorophore-conjugated antibodies were from BD 
Biosciences, unless otherwise noted. For mature hematopoietic lineage analysis, 
we used the following panel of antibodies: anti-CD45.1-APC, anti-CD45.2-
PerCP-Cy5.5, anti-CD3e-FITC, anti-B220-HorizonV500, anti-CD8-PacificBlue, 
anti-CD4-APC eFluor 780 (eBiosciences), anti-11b/Mac1-PE, anti-Ly6G/Gr1-PE-
Cy7 with or without biotinylated anti-Ter119 and streptavidin-conjugated PE-
Texas Red (Molecular Probes, Invitrogen). For progenitor cell analysis, we used 
the following panel: FITC-conjugated anti-lineage markers (CD4, CD4, CD8, 
B220, Mac1, Gr1, Ter119), anti-CD16/32-PE, anti-CD34-PacificBlue, anti-Sca1-
APC-Cy7, and anti-c-Kit-PerCP-Cy5.5. For HSC analysis, we used the following 
panel: anti-lineage-FITC, as above, anti-CD48-FITC (eBiosciences), anti-CD41-
FITC (eBiosciences), anti-CD150-APC (eBiosciences), anti-Sca1-APC-Cy7, and 
anti-c-Kit-PerCP-Cy5.5. For single-cell sorting of HSCs in colony assays, we 
used the same, but without anti-c-Kit-PerCP-Cy5.5 to prevent possible 
interference at the c-kit receptor tyrosine kinase during subsequent stimulation 
with SCF. In BrdU/PI experiments, we substituted anti-Sca1-PE-Cy7 and anti-c-
Kit-APC-Cy7 antibodies to reduce detector spillover from the PI dye. In 
Hoechst/Pyronin Y experiments, we used anti-lineage-FITC, as above, anti-
CD48-FITC (eBiosciences), anti-CD41-FITC (eBiosciences), anti-CD150-APC 
(eBiosciences), and anti-Sca1-APC-Cy7. 
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BrdU HSC Analysis 
For bromodeoxyuridine (BrdU) incorporation experiments, mice were 
injected I.P. using a 27-gauge 0.5” needle for four days with 2 mg of 
bromodeoxyuridine (Sigma) dissolved at 10 mg/mL in PBS, starting two days 
after the last dose of polyIC. The day after the last dose, mice were killed and 
bone marrow cells isolated as described above. Extracted marrow cells were 
then stained with cell surface protein antibodies directed against HSC cell 
surface markers and subsequently fixed and permeabilized according to the 
manufacturer’s protocol (BrdU Flow Kit, BD Biosciences). Briefly, cells were 
washed with flow buffer, permeabilized by incubation with 100 μL of BD 
Cytofix/Cytoperm for 15 minutes at room temperature, washed in 1 mL BD Wash 
Buffer (which contains the permeabilizing reagent saponin), re-fixed in 100 μL BD 
Cytofix/Cytoperm Plus (or either substituted with 10% DMSO/Cytofix/Cytoperm 
or freezing at -80°C in 90% FBS/10% DMSO, according to BD’s alternate 
protocol) for 10 minutes on ice, washed in 1 mL BD Wash Buffer, and re-fixed in 
Cytofix/Cytoperm for 5 minutes at room temperature. After further washing in 1 
mL BD wash buffer, cells were incubated with 30 μg DNAse for one hour at 37°C 
to expose BrdU binding sites, washed in 1 mL BD Wash Buffer, stained with 
saturating concentration of anti-BrdU-PacificBlue, and resuspended with 0.125 
μg PI in 100 μL flow buffer. Cells were then analyzed by flow cytometry on an 
LSR II flow cytometer, as described in the section entitled Flow Cytometry. 
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PY/Hst HSC Analysis 
For Pyronin Y(PY)/Hoechst (Hst) experiments, marrow cells were 
incubated for 30 minutes at 37°C in 1 mL per 106 cells of 3.33 μM Hoechst 33342 
(Invitrogen) in a solution of 10% FBS/20 mM HEPES/0.1% dextrose/PBS. 
Without washing, 10 μL of concentrated PY (Sigma) was added (final = 1 μg/mL 
PY) and the cells incubated for 30 minutes at 37°C, followed by washing and 
HSC antibody incubation, as above. Cells were continuously stored on ice and 
immediately processed by flow cytometry. 
Marrow Enrichment 
In some experiments, including BrdU and PY/Hst-based experiments, low-
density bone marrow cells were first enriched by lineage depletion or by c-kit 
selection using the MACS Lineage Depletion or C-kit Isolation kits (Miltenyi 
Biotec), according to the manufacturer’s protocol. Briefly, bone marrow cells were 
incubated with biotinylated lineage antibody cocktail or anti-c-kit antibody-
conjugated beads in MACS buffer (PBS with 0.5% BSA and EDTA). For lineage 
depletion, cells were then incubated with streptavidin-conjugated magnetic 
beads, passed through an LS magnetic column (Miltenyi), and the flow-through 
collected as lineage depleted cells. For c-kit enrichment, antibody-treated bone 
marrow cells were passed through an MS magnetic column (Miltenyi), the flow-
through discarded, and the adherent cells (i.e. c-kit+) washed from the column 
and collected. Cells were then washed in PBS or flow buffer for further 
experiments. 
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Pcl7CREeGFP Generation 
The pcl7eGFP lentiviral construct was a kind gift of Helmut Hannenberg at 
the Indiana University School of Medicine. This construct contains an eGFP 
cassette and a multiple cloning site (MCS) downstream of the spleen focus-
forming virus (SFFV) promoter, which potently drives transcription in eukaryotic 
cells. The eGFP cassette was swapped with a CREeGFP fusion construct 
(Addgene), inserted between the MCS and the BsrgI site at the C-terminus of 
eGFP, using standard molecular cloning techniques.  
Virus Generation 
To generate virus, NIH 293T cells at 95% confluence on 10 cm dishes 
were transfected with 5 μg each of pcl7CREeGFP or pcl7eGFP, gag-pol 
expressing plasmid, and foamyviral envelope plasmid (pCOPE01) in 6 mL 
Dulbecoo’s Modified Eagle Media (DMEM, Gibco/Invitrogen) containing 10% 
FBS and 0.0075 mg/mL polyethyleneimine (PEI, Sigma). After overnight 
transfection at 37°C, transfection media was aspirated and replaced with 6 mL 
fresh DMEM containing 10% FBS, 50 U/mL penicillin, 50 μg/mL streptomycin-
streptomycin, 2 mM L-Glutamine, and 10% FBS. After 24 hours, all supernatants 
were collected, like cultures pooled (to 30 mL maximum), filtered through a 0.22 
μm polyethersulfone (PES) membrane Stericup unit (Millipore), and centrifuged 
at 25-30,000x g at 4°C for 2 hours in a polycarbonate Oak Ridge centrifuge tube 
(Nalgene). Supernatant was decanted, bleached, and disposed in biohazardous 
waste, and the viral pellet resuspended in 1 mL IMDM containing 20% FBS. 
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Virus was stored in aliquots at -80°C and all thawed sample was either 
immediately used or appropriately discarded. Viral titer (infectious particles per 
mL) was determined by percent GFP-positivity of serially transduced HT1080 
cells, plated at 100,000 per well of a six well plate in 1 mL DMEM/10% FBS. The 
serial dilution started at 10-3 dilution from stock and ended with 10-8 dilution. The 
following equation was used for titer computation: 
 
ܶ݅ݐ݁ݎ	 ൬݂݅݊݁ܿݐ݅݋ݑݏ ݌ܽݎݐ݈݅ܿ݁ݏ݉ܮ ൰ ൌ
ܩܨܲ	݈݈ܿ݁ݏ	%	 ∗ 	100,000	ݐ݋ݐ݈ܽ	݈݈ܿ݁ݏ
1	݉ܮ	݉݁݀݅ܽ	 ∗ 	10ି௫	݈݀݅ݑݐ݅݋݊	݂ܽܿݐ݋ݎ 
 
Viral Transduction  
A similar protocol was used for the transduction of both low density 
mononuclear cells and of mature mast cells. Briefly, each well of a six-well plate 
was coated overnight at 4°C or for four hours at room temperature with 40 μg 
recombinant fibronectin (Retronectin, Takara) in 1 mL PBS. This fibronectin/PBS 
solution was aspirated and replaced with 50-100 infectious particles per target 
cell (mononuclear or mast cell) diluted in a 1 mL solution of IMDM containing 
20% FBS, 50 U/mL penicillin, 50 μg/mL streptomycin-streptomycin, 2 mM L-
Glutamine supplemented with either 100 ng/mL SCF, 10 ng/mL IL-6, and 10 
ng/mL IL-3 (mononuclear cell transduction protocol) or only 10 ng/mL IL-3 (mast 
cell transduction protocol). After one hour virus/fibronectin incubation at 37°C, 1-
2 million target cells were added in a 50 μL volume of the aforementioned 
transduction media to each 1 mL solution containing well. After 16 to 24 hours of 
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incubation at 37°C, the cells were harvested, washed in IMDM, and resuspended 
in appropriate culture media or immediately used for experiments. 
Mast Cell Culture 
To generate mast cells in tissue culture, non-adherent low-density bone 
marrow cells (isolated as described above) were passaged twice weekly for 4-6 
weeks in mast cell media (“MCM”: IMDM containing 10% FBS, 50 U/mL 
penicillin, 50 μg/mL streptomycin-streptomycin, and 2 mM L-Glutamine 
supplemented with 7.5 ng/mL interleukin-3 (IL-3, Peprotech)), as described 
previously (87, 146). Mast cells were identified by characteristic morphology on 
Giemsa/toluidine blue staining and via flow cytometry with fluorescently 
conjugated primary antibodies directed against FcεR and c-kit, as described 
previously (98). After four weeks of culture in IL-3, mast cell purity (FcεR+c-kit+) 
approached 95% of the culture population. Actual culture homogeneity is shown 
in the results section. 
Inhibitors 
The Mek-Erk inhibitor PD0325901 was purchased from Cayman 
Chemicals, dissolved at 10 mM in DMSO, stored in 10 μL aliquots at -20°C, and 
diluted fresh in cell culture media for each experiment to a concentrated solution 
of 100 μM (~1000x). Final concentrations are indicated in specific experiments 
and range from 10 to 800 nM. Final DMSO concentration in PD0325901-based 
experiments was < 0.008%, and equivalent DMSO concentrations were applied 
to non-treated samples. Samples were pre-incubated with inhibitor or DMSO only 
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for about one hour at 37°C prior to stimulation. SB203580 (p38 inhibitor), 
SP600125 (JNK inhibitor), rapamycin (mTOR inhibitor), FH535 (β-catenin 
inhibitor) and LY-294002 (PI-3K inhibitor) were all purchased from Sigma, 
dissolved to a 1000x stock solution in DMSO, and used at indicated 
concentrations.  
Mast Cell Proliferation Assays 
Hemcytometer-based: Four- to six-week old mast cells were deprived of 
IL-3 and FBS for 16 to 20 hours (“overnight”) and then resuspended in RPMI or 
IMDM with 10% FBS, 50 U/mL penicillin, 50 μg/mL streptomycin-streptomycin, 
and 2 mM L-Glutamine. Cells were standardized to a concentration of 2 to 4x105 
cells per mL and then 1 mL placed into each well of a 24-well plate. Cells were 
stimulated with recombinant murine SCF, at the concentrations indicated in 
individual experiments. For each condition, duplicate or triplicate wells were 
assayed. After 72 hours at 37°C, viable mast cells were counted by 
hemcytometer with trypan blue exclusion using an inverted light microscope. The 
single value for each individual sample was considered the mean of the 
replicates. The standard error of the mean was computed from multiple means of 
biologically-independent samples. 
MTT-based: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide- 
(MTT)-based assay of mast cell proliferation/cellularity was performed according 
to the manufacturer’s protocol (Roche). As above, mast cells were deprived of 
growth factors overnight and then resuspended in RPMI or IMDM with 10% FBS, 
50 U/mL penicillin, 50 μg/mL streptomycin-streptomycin, and 2 mM L-Glutamine. 
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A total of 32,500 cells were plated per well of a 96-well plate in 100 μL final 
volume (final concentration was 3.25x105 cell per mL). Cells were stimulated with 
recombinant murine SCF, at concentrations ranging from 10 to 100 ng/mL. For 
each condition, quadruplicate or sextuplet wells were assayed. At 24, 48, and 72 
hours following SCF stimulation at 37°C, MTT reagent (Roche, 10 μL) was added 
to each well and the cells incubated for four hours at 37°C. Next, solubilization 
buffer (Roche, 100 μL) was added and the cells incubated overnight at 37°C. 
Absorbance was read by spectrophotometer at 550 nm wavelength (Molecular 
Devices). Wells containing media only were used as reference/blank, which was 
averaged and subtracted from all sample values prior to analysis. Data were 
acquired with SoftMax Pro software (Molecular Devices). The mean value of all 
replicates for a sample was considered the single value for an individual sample. 
Using these single values for biologically-independent samples, the standard 
error of the mean was computed. 
3H-Thymidine-based: Mast cells were deprived of growth factors overnight 
and then resuspended in IMDM with 50 U/mL penicillin, 50 μg/mL streptomycin-
streptomycin, and 2 mM L-Glutamine. A total of 50,000 cells were plated per well 
of a 96-well plate in 100 μL final volume (final concentration was 5.0x105 cell per 
mL). Between four and six replicates of each condition were typically assayed. 
Cells were pre-treated one hour with the indicated concentrations of PD0325901 
or vehicle alone and subsequently stimulated with 10% FBS and 80 ng/mL SCF 
supplemented with 1 μCi 3H-thymidine. In some experiments, 1 μCi 3H-thymidine 
was added 16 hours after SCF/FBS stimulation. For experiments with multiple 
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time points, identical plates were established for each condition, and plates were 
placed at -20°C to stop proliferation at the indicated time point. After the 
conclusion of the experiment, all plates were thawed and assayed at the same 
time. Measurement of 3H-thymidine incorporation was performed with a 
Beckman-Coulter scintillation counter. Given high inter-well variability secondary 
to imprecision in the high-throughput scintillation counter, the highest and lowest 
values among replicates were eliminated, in an unbiased manner, and the 
remaining values used to compute a mean value. In all cases, standard errors of 
the mean are presented only if multiple mean values from biologically-
independent samples were obtained. 
Mast Cell Cycle Analysis 
Four- to six-week old mast cells were deprived of IL-3 and FBS overnight 
and then resuspended in IMDM with 0.5%-1.0% BSA, 50 U/mL penicillin, 50 
μg/mL streptomycin-streptomycin, and 2 mM L-Glutamine. Cells were 
standardized to a concentration of 2.25x106 cells per mL and then 4 mL placed in 
15 mL conical Falcon tubes. Some samples were pre-incubated with 100 nM 
PD0325901. Cells were then stimulated with 80 ng/mL recombinant murine SCF 
and 10% FBS, aliquoted to 1.6 mL Eppendorf tubes, allowed to grow for 24 hours 
at 5% CO2/37°C, then pulsed with 10 μM BrdU for 2 hours. After BrdU pulse, 
cells were washed with PBS to remove the unincorporated BrdU. Some cultures 
were then re-treated with 100 nM PD0325901. Cells were then stopped by 
addition of 100 μL BD Cytofix/Cytoperm solution at three, six, and twelve hours 
following the BrdU pulse. Cells were washed in 1 mL flow buffer and stored at -
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80°C in 300 μL 90% FBS/10% DMSO. After thawing, the BD BrdU Flow protocol 
was followed, starting with the five minute re-fixation in 100 μL BD 
Cytofix/Cytoperm, as described above. In this experiment APC-conjugated BrdU 
antibody (instead of PacificBlue-conjugated) was used to detect BrdU 
incorporation, and 20 μL 7-AAD solution was used to detect nuclear content. 
Samples were analyzed with a FACSCalibur flow cytometer equipped with blue 
and red lasers. 
Mast Cell Survival Assay 
Four- to six-week old mast cells were deprived of IL-3 and FBS overnight 
and then resuspended in RPMI or IMDM with 0.5%-1.0% BSA, 50 U/mL 
penicillin, 50 μg/mL streptomycin-streptomycin, and 2 mM L-Glutamine. Cells 
were standardized to a concentration of 2x105 cells per mL and then 1 mL placed 
into each well of a 24-well plate. Cells were stimulated with recombinant murine 
SCF (without FBS), at the concentrations indicated in individual experiments. For 
each condition, duplicate or triplicate wells were assayed. After 72 hours at 37°C, 
viable mast cells were counted by hemcytometer on light microscopy, with trypan 
blue exclusion. The single value for each individual sample was considered the 
mean of the replicates. The standard error of the mean was computed from 
multiple means of biologically-independent samples. 
Deconvolution Microscopy 
Four- to six-week old mast cells were deprived of IL-3 and FBS overnight. 
In some experiments, mast cells were deprived of only IL-3 overnight (i.e. 
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cytokine-deprived). The cells were then resuspended in RPMI or IMDM with 
0.5%-1.0% BSA or with 10% FBS, as indicated, 50 U/mL penicillin, 50 μg/mL 
streptomycin-streptomycin, and 2 mM L-Glutamine. Cells were standardized to a 
concentration of 2.5x106 cells per mL, pre-incubated with PD0325901, where 
indicated, and stimulated with 80 ng/mL recombinant murine SCF and/or with 
10% FBS at 5% CO2/37°C. Cells were aliquoted to 1.6 mL Eppendorf tubes and 
the stimulated terminated by addition of 4% paraformaldehyde for 15 minutes at 
room temperature. After, fixation, cells were resuspended in 1 mL PBS. 
Approximately 200,000 cells were then loaded in PBS onto a cytospin funnel 
mounted to a glass slide and spun for 10 minutes at 800 g. Following cytospin, 
fixed cells were extracted by washing in 0.3% Triton-X, blocked in 5% FBS, 
incubated with primary antibody in 0.1% BSA/PBS overnight at 4°C, washed 
three times in PBS, and subsequently incubated for one hour at room 
temperature with fluorophore-conjugated anti-mouse or anti-rabbit antibodies 
(Molecular Probes, Invitrogen). After washing, one drop of a DAPI mounting 
solution (Molecular Probes, Invitrogen) was applied and a cover slip sealed over 
the samples using lacquer. Data were acquired on a DeltaVision deconvolving 
microscopy system (Applied Precision) and analyzed with ImageJ. Typical 
controls included cells incubated with secondary (fluorophore-conjugated) 
antibody but not primary antibody. 
Cytokine Array 
To screen for cytokines potently induced to secretion by SCF-stimulation, 
we performed a qualitative assessment using an immunoblot-based array 
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(Mouse Cytokine Array Panel A, R&D Systems). Six-week old mast cells were 
deprived of IL-3 and FBS overnight and then resuspended in RPMI with 0.5% 
BSA, 50 U/mL penicillin, 50 μg/mL streptomycin-streptomycin, and 2 mM L-
Glutamine. Cells were standardized to a concentration of 2.5x106 cells per mL 
and then 2 mL per condition placed in 15 mL Falcon tubes. Cells were then 
stimulated with 50 ng/mL SCF for six hours at 5% CO2/37°C, and centrifuged. 
The supernatant was then harvested and stored at -20°C. After thawing, the 
cytokine array experiment was performed on the mast cell supernatants 
according to the manufacturer’s protocol. Briefly, array membranes, which are 
pre-coated with antibodies to 40 known mouse cytokines and growth factor, were 
blocked in 2 mL Array Buffer 6, washed, and then incubated with 1.5 mL mast 
cell supernatant treated with Array Buffer 4, Array Buffer 5, and 15 μL Detection 
Antibody Cocktail. After overnight incubation at 4°C with gentle rocking, 
membranes were washed and then incubated with streptavidin-conjugated 
horseradish peroxidase (streptavidin-HRP). Following washes, conjugated 
enzyme was detected by enhanced chemiluminescence (ECL, Amersham, GE 
Healthcare). Signal density was measured using NIH free software (ImageJ). 
Background intensity was averaged and subtracted from all sample values. 
Supernatants from non-stimulated mast cells served as control. 
Multiplex Assay 
Five-week old mast cells were deprived of IL-3 and FBS overnight and 
then resuspended in IMDM with 1.0% BSA, 50 U/mL penicillin, 50 μg/mL 
streptomycin-streptomycin, and 2 mM L-Glutamine. Cells were standardized to a 
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concentration of 2.5x106 cells per mL and then 200 μL placed into each well of a 
96-well round bottom plate. Cells were pre-incubated with inhibitors, as indicated, 
and then stimulated with recombinant murine SCF, at the concentrations 
indicated. After 6 hours at 37°C, the 96-well plate was centrifuged for 10 minutes 
at 800g, and the supernatant carefully transferred to a new 96-well plate and 
stored at -80°C. Cytokines and growth factors were assayed with multiplex 
simultaneous quantification of ten fluorescent antibody capture beads directed 
against M-CSF, TNF-α, MCP-1, MIP-1α, MIP-1β, G-CSF, GM-CSF, IL-10, IL-13, 
IL-6. These cytokines were selected based on preliminary screening experiments 
using the cytokine array detection kit (see above).The multiplex assay was 
performed according to the manufacturer’s protocol (Millipore Milliplex). Briefly, 
25 μL of mast cell supernatant was incubated with analyte antibody capture 
beads, washed three times with provided buffer, incubated with secondary 
antibody containing streptavidin-PE, washed three times, suspended in 100 μL 
sheath fluid (i.e. saline), and analyzed on a Luminex 200 cytometer with 
StarStation software (Luminex). Standard curves were computed using a cubic 
spline fit, according to the manufacturer’s instruction. 
Western Blotting 
Sample isolation: Four- to six-week old mast cells were deprived of IL-3 
and FBS overnight. In some experiments, mast cells were deprived of only IL-3 
overnight (i.e. cytokine-deprived). The cells were then resuspended in RPMI or 
IMDM with 0.5%-1.0% BSA or with 10% FBS, as indicated, 50 U/mL penicillin, 50 
μg/mL streptomycin-streptomycin, and 2 mM L-Glutamine. Cells were 
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standardized to a concentration of 2.5x106 cells per mL and pre-incubated, as 
indicated, with PD0325901 or with vehicle alone. Each sample was stimulated 
with the indicated concentration of SCF and then one to 1.5 mL of cells aliquoted 
to individual 1.6 mL Eppendorf tubes for each time point following stimulation. At 
the indicated time point, tubes were placed on ice and immediately centrifuged 
for 3 minutes at 1200g at 4°C. After carefully aspirating the supernatant, SDS-
PAGE buffer containing β-mercaptoethanol was added at a final concentration of 
1 μL buffer per 5,000-20,000 cells, depending on the experiment. Cells in SDS-
PAGE were then sonicated and clarified by centrifugation. In some experiments, 
protein lysis buffer (ProteoJet, Fermentas, ThermoFisher) supplemented with 
Complete Mini Protease Inhibitor Cocktail (Roche), sodium fluoride, and sodium 
orthovananate was used instead of SDS-PAGE buffer for initial isolation, followed 
by clarification of supernatant, quantification of protein by the bicinchoninic acid 
method (BCA, Thermo Scientific), standardization, and suspension in SDS-
PAGE buffer. After sample standardization, equivalent quantities were loaded 
into a 4-12% Bis-Tris gel (Invitrogen) and electrophoresed. Electrophoresed 
samples were transferred to PVDF membrane for immunoblotting. 
Immunoblotting protocol: PVDF membranes were blocked for more than 
24 hours in 5% non-fat milk/0.01% NaN3/PBS. Samples were then incubated with 
antibodies in 5% non-fat milk in PBS overnight with gentle rocking. Following 
three to six washes in 0.1% Tween-20/PBS, membranes were incubated for one 
hour with mouse or rabbit anti-Fc antibody conjugated to streptavidin (GE 
Healthcare) diluted 1:5000 in 0.5-2% non-fat milk in PBS. Following three to six 
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more washes, HRP enzyme was detected with ECL or SuperSignal West Dura 
chemiluminescent kit (ThermoScientific), according to the manufacturers’ 
protocols. Signal density was measured using NIH free software (ImageJ). 
Quantification of Mast Cells In Vivo 
Following previously described protocols (98, 147), WT BoyJ mice which 
had been reconstituted with WT, E1-KO, and E2-KO hematopoietic stem cells for 
approximately one year were given an infusion of SCF or vehicle (PBS) via 
micro-osmotic pumps (Alzet). Pumps were placed subcutaneously at the mid-
flank. The micro-osmotic pumps released SCF or vehicle at a rate of 0.5 μL an 
hour over the course of seven days. After killing the mice, approximately one to 
two cm sections of skin were excised, fixed in phosphate buffered 10% formalin, 
embedded in paraffin, and section at 10 micron. Sections were then stained with 
toluidine blue to identify mast cells. Cells were quantified by counting 2-mm2 
sections. 
PD0325901 Treatment of Plexiform Neurofibroma Model 
The Nf1flox/-; PeriostinCre+ tumor model was used to assess in vivo 
efficacy of PD0325901 treatment in modulating the hematopoietic inflammation 
associated with plexiform neurofibroma development. Five tumor model mice 
with PET-CT-verified plexiform neurofibromas were fed with drug by oral gavage 
every day for six weeks. The dose was 12.5 mg/kg PD0325901 in a solution of 
0.5% methylcellulose/0.2% Tween-80 in water at a concentration of 12.5 mg/mL. 
A typical dose comprised 200 μL of solution. After the six-week treatment, all 
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mice were killed and assessed by histology of the dorsal root ganglia, as 
described previously (24). 
Statistics 
All statistical analyses were performed with GraphPad Prism 5.0. One- or 
two-way ANOVA was performed, as appropriate, with Bonferroni post-hoc 
corrections. For two variable comparisons, unpaired two-tailed student’s t tests 
were used. All tests, number of biologically-independent replicates, and 
significance levels are found within the figure legends.  
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RESULTS 
Erk and Hematopoiesis 
To test the consequence of Erk disruption in hematopoietic stem and 
progenitor cells, we employed two primary methods. First, we performed 
functional and descriptive studies of the bone marrow cells harvested from mice 
disrupted for Erk1, Erk2, and Erk1/2. Second, we transplanted Erk mutant 
hematopoietic stem cells in a competitive fashion into lethally-irradiated WT host 
mice, waited for complete hematopoietic reconstitution, induced Cre expression, 
and performed long-term hematopoietic studies in vivo.  
Inducible deletion of Erk1/2 in the bone marrow. 
We intercrossed Erk1 knockout mice with conditional knockout (“floxed”) 
Erk2 mice (104), generating Erk1-/-Erk2flox/flox animals. We bred these Erk1-/-
Erk2flox/flox mice with mice bearing the Mx1Cre transgene, an inducible construct 
expressing in all marrow cells, including but not limited to hematopoietic stem 
and progenitor cells (Figure 3a) (143, 144, 148). We analyzed four genotypes: 
Erk2flox/flox (WT), Erk1-/-Erk2flox/flox (E1-KO), Erk2flox/floxMx1Cre+ (E2-KO), and Erk1-
/-Erk2flox/floxMx1Cre+ (DKO) (Figure 3a-b). After moderate polyIC dosing, E2-KO 
mice had efficient Erk2 deletion, but putative DKO mice required extended doses 
(20-25 μg/g body weight, seven doses) to achieve low/undetectable Erk2 levels 
(Figure 3c). Moreover, DKO primary mutants succumbed to various 
complications during or within six weeks of Cre induction, suggesting a critical 
requirement for one Erk isoform in hematopoietic and/or non-hematopoietic 
tissues. Particularly, we found that Mx1Cre+ potently drives Erk2flox/flox excision in 
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hepatic tissue, precluding our ability to eliminate the possibility that liver toxicity 
induced lethality in non-transplanted animals.  
Of note, we administered the same weight-based polyIC regimen to all 
mice, regardless of genotype, throughout the following studies. We also 
performed experiments at varying times after the last dose of polyIC, although 
typically within one to five days after, as indicated in individual experiments. The 
imminent death and hematopoietic gene excision instability of the DKO animals 
prevented us from waiting longer. To circumvent these complications, we 
performed our paramount hematopoietic studies in long-term transplanted 
animals, as discussed later. 
Figure 3a 
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 Figure 3b
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Figure 3: Model system and successful Erk deletion in the bone marrow. 
Erk1-/- mice, Erk2flox/flox mice, and Mx1Cre+ mice were intercrossed according to 
the indicated schema (a). Essential breeding (i.e. experimental) genotypes are 
indicated in gray. After creation of the desired Erk mutant and Mx1Cre+ mice, 
purebred mice were interbred with their Mx1Cre- littermates to generate Cre+ and 
Cre- littermates for all experiments. Flox: flanking loxp sites. For ease, WT, E1-
KO, E2-KO, and DKO are the nomenclature used throughout, indicative of the 
shown genotypes (b). The extended polyIC regimen (20-25 μg/g body weight, 7 
doses, every other day) led to undetectable Erk2 in Mx1Cre+, as detected by 
anti-Erk1/2 antibody immunoblot of whole bone marrow cells (c).  
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Loss of myeloid cellularity and granulocytes in DKO bone marrow. 
Given previous findings from lymphocyte-focused studies of Erk1/2 
disruption in the hematopoietic system (including excision driven by Mx1Cre 
(105)), we did not anticipate a gross myeloid phenotype. However, we found a 
two to two-and-a-half fold reduction in total marrow cellularity (Figure 4), which 
corresponded to striking histological changes, including diminished white blood 
cellularity, vacant marrow spaces, and distended sinuses (Figure 5a). By flow 
cytometry, we found a prominent reduction in the frequency of the characteristic 
myeloid FSChiSSChi population (Figure 5a, bottom row). Intriguingly, we observed 
none of these deficiencies in single KO animals.  
Quantitative analyses of these flow cytometry data revealed diminished 
myeloid cells as a frequency and as a total quantity of bone marrow cells (Figure 
5b). Moreover, while the characteristic lymphocyte FSClowSSClow population was 
increased as a frequency, adjustment for total cellularity revealed no change 
overall (Figure 5b, bottom graph). Thus, in these short-term experiments, the 
redistribution from the characteristic myeloid scatter to lymphoid scatter 
principally resulted from a loss in total myeloid cells and not from a change in the 
putative lymphoid population. 
To further examine marrow composition, we employed eleven-parameter 
flow cytometry capable of simultaneously assaying the expression of the major 
cell surface proteins marking hematopoietic lineage commitment. These markers 
included Gr1 (granulocytes), Mac1 (monocytes), B220 (B cells), CD3 (T cells), 
CD4, CD8, and Ter119 (erythroid cells). Accurate identification of mature myeloid 
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lineages requires initial gating on the non-lymphocyte population, as activated 
lymphocytes can express some myeloid markers. Accordingly, cells were first 
gated on CD3- and B220- using unbiased histogram analyses based on 
fluorescence-minus-one controls. In doing so, we found prominent reductions in 
the frequency and absolute number of strictly-defined mixed marrow 
granulocytes (CD3-B220-Gr1+Mac1+), as shown qualitatively (Figure 6a) and 
quantitatively, both as a frequency and as adjusted for the reduced overall 
cellularity (Figure 6b), recapitulating and extending the initial findings from the 
abnormal redistribution in forward and side scatters.  
To detect a possible unexplained induction of lymphocyte marker 
expression on myeloid cells in the DKO samples, we also examined the absolute 
frequency of Gr1+ and/or Mac1+ expressing cells (without CD3-B220- gating). As 
above, the frequency of absolute Gr1+ or Mac1+ cells were reduced (Figure 7a, 
top panel). Moreover, although the frequency of cells expressing lymphocyte 
markers was increased in DKO samples (Figure 7a, bottom panel; Figure 7b, top 
graph), the total number of B220+ and CD3+CD4+ cells were diminished while the 
total number of CD3+CD8+ cells remained unchanged (Figure 7b, bottom graph). 
In the short-term, dual Erk1/2 disruption in the bone marrow dramatically 
diminishes total cellularity, which principally results from reduced granulocyte 
numbers. Moreover, short-term Erk1/2 disruption moderately reduces B 
lymphocyte and CD4+ T lymphocyte cellularity. By contrast, single isoform 
disruption produces no distinct phenotype from WT samples.
Figure 4 
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Figure 4: Reduced overall cellularity of DKO bone marrow. DKO samples 
show a 2 to 2.5-fold reduction in total low density bone marrow cellularity, as 
quantified per femur. E1-KO and E2-KO bone marrow samples show no 
difference from WT (n = 3-7, **p<0.01 vs. all groups, 1-way ANOVA with 
Bonferroni correction). Error bars represent the standard error of the mean. 
These data are representative of at least five separate experiments with multiple 
biologically independent replicates per experiment.  
Figure 5a
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Figure 5: Histological and flow cytometric analyses show loss of DKO bone 
marrow myeloid cellularity. The reduction in total DKO bone marrow cellularity 
corresponds to vacant marrow spaces and distended sinuses, as shown at 100x 
and 400x by H&E stain of 8 μM femoral sections on light microscopy (a, top two 
rows). By flow cytometric analyses, the DKO samples show a prominent shift in 
frequency from the characteristic myeloid FSChiSSChi population to a lymphoid 
FSClowSSClow population (a, bottom row). These data are quantified as a 
frequency and by total number of cells in the two graphs, revealing a preferential 
reduction in the absolute number of the characteristic myeloid population (b) 
(n=3-7, **p<0.01, ***p<0.001, DKO vs. all, 2-way ANOVA with Bonferroni 
correction). Error bars represent the standard error of the mean. These data are 
representative of several experiments, each with multiple biologically-
independent replicates per experiment.  
Figure 6a
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Figure 6b 
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Figure 6: Reduction in the frequency and absolute number of DKO marrow 
granulocytes. Bone marrow cells were incubated with saturating concentrations 
of nine distinct fluorophore-conjugated antibodies directed against cell surface 
markers of mature hematopoietic lineages. Granulocytes were defined as the 
CD3-B220-Gr1+Mac1+ population, representing mixed marrow mature and 
immediate precursor granular cells. DKO samples showed preferential reduction 
in this population, as demonstrated by representative flow cytometry (a, gated on 
CD3-B220-) and as quantified by frequency (b, top) and total cellularity (b, 
bottom, all gated on CD3-B220-; for both graphs, n=7, *p<0.05, ***p<0.001, 2-way 
ANOVA with Bonferroni correction). Error bars represent the standard error of the 
mean.  
Figure 7a
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Figure 7: Absolute reduction in DKO myeloid markers and in total lymphoid 
cellularity. Ungated flow cytometric analyses of individual myeloid markers 
shows reduced frequency of total DKO Gr1+ and Mac1+ marrow cells with no 
difference in the frequency of Ter119+ cells (a) (representative of n=7). While 
DKO marrow shows increased frequency of cells positive for lymphocyte markers 
(B220, CD3, CD4, CD8), quantification reveals that total lymphoid cell number is 
still depressed in DKO marrow (b) (n=7, **p<0.01, ***p<0.001, 2-way ANOVA 
with Bonferroni correction). Error bars represent the standard error of the mean.
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Loss of myeloid colony formation in DKO bone marrow. 
To test if this observed loss of myeloid cellularity arises in myeloid 
precursors (versus apoptosis or other deficiency in mature monocytes and 
granulocytes), we performed colony assays on enriched methylcellulose with 
saturating concentrations of SCF, EPO, IL-3, GM-CSF, M-CSF, and G-CSF. This 
combination of cytokines induces clonal proliferation and differentiation of 
progenitors along the entire myelopoietic hierarchy, from the hematopoietic stem 
cell to late-stage monocytic and granulocytic precursors (see Figure 1).  
Through these assays, we found that mixed DKO precursors produced 
few, if any, colonies, with no differences detected among E1-KO, E2-KO, and WT 
specimens (Figure 8). Intriguingly, protein analysis of the few DKO colonies 
revealed an outgrowth of Erk2-expressing progenitors (i.e. E1-KO cells), 
indicating that only those cells escaping Cre-mediated recombination (and, thus, 
disruption of Erk2) can produce colonies. As expected, adjustment of these data 
for loss of femoral bone marrow cellularity further accentuates the diminution in 
DKO colony production while revealing no difference in single KO samples (data 
not shown). We performed additional colony assays using single and varied 
combinations of cytokines (e.g. IL-3 alone, IL-3 in combination with SCF, as 
discussed later), largely recapitulating the results from the mixed myeloid colony 
assay 
To further assess the hematopoietic capacity of DKO bone marrow, we 
performed low and high proliferative potential cell colony forming unit assays 
(LPPC-CFU and HPPC-CFU). While using similar combinations of myelopoietic 
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cytokines, these experiments rely on different experimental conditions (e.g. agar-
based media, longer growth term, lower oxygen tension) to encourage the clonal 
outgrowth of hematopoietic stem and multipotent progenitor cells. By definition, 
these colonies have a large, dense core and can be replated to grow more 
colonies, thus demonstrating high clonal proliferative potential. In practice, this 
assay approximates the more primitive hematopoietic potential of an admixed 
population of bone marrow cells. As part of the assay, colonies resembling mixed 
myeloid colonies can be observed after one week of growth (LPPC colonies). In 
these experiments, we found no quantitative differences among WT, E1-KO, and 
E2-KO bone marrow cells in their capacity to produce colonies (Figure 9). 
However, as above, DKO bone marrow cells produced few, if any, colonies. 
Although we did not detect differences among the E1-KO, E2-KO, and WT 
bone marrow cells in our initial analyses, we caution against generalizing that 
individual Erk isoforms are dispensable for the generation of all myeloid lineages. 
It should be noted that the aforementioned experiments assess gross myeloid 
phenotypes using high doses of multiple myeloid- and early progenitor cell-acting 
cytokines. Indeed, in lineage-specific analyses not depicted here, lower 
concentrations and combinations of particular myelopoietic cytokines produce 
intriguing, isoform-dependent results, especially when considering functional 
aspects of particular lineages. For example, we have found that E1-KO bone 
marrow cells demonstrate a diminished capacity to produce osteoclast colonies 
in M-CSF/RANKL supplemented methylcellulose, while E2-KO bone marrow 
cells demonstrate no deficiency as compared to WT cells. While these data are 
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not shown here, they are currently submitted for publication as part of a 
manuscript. Thus, in the currently discussed hematopoietic investigation, we are 
assessing only gross hematopoietic and myeloid phenotypes, principally 
concerning WT versus DKO cells. We reiterate, with caution, that specific 
hematopoietic cell types may depend on variable doses of Erk1 and/or Erk2 for 
their generation and function, and that subtler functional assays may be required 
to detect these phenotypes.  
Figure 8 
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Figure 8: Myeloid colony formation requires one isoform of Erk. While WT, 
E1-KO, and E2-KO bone marrow cells produced similar numbers of colonies, 
DKO cells formed few mixed myeloid colonies in methylcellulose supplemented 
with SCF, IL-3, EPO, GM-CSF, G-CSF, and M-CSF (n=3-4, **p<0.01 vs. all, 1-
way ANOVA with Bonferroni correction). Error bars represent the standard error 
of the mean. These results are representative of at least three experiments 
performed on separate occasions, each with multiple biologically-independent 
replicates. Each biologically independent sample was plated in triplicate, and the 
mean number of colonies formed per plate was considered the value for the 
sample.
Figure 9 
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Figure 9: Hematopoietic stem and multipotent progenitor cell colony 
formation requires one isoform of Erk. As with the assays on methylcellulose, 
DKO bone marrow cells produced few colonies in LPPC and HPPC assays, 
experiments which encourage the clonal outgrowth of multipotent progenitor 
cells. No difference was detected among WT, E1-KO, and E2-KO bone marrow 
cells in their capacity to form LPPC/HPPC colonies. Cytokines included SCF, IL-
3, EPO, GM-CSF, M-CSF, and G-CSF (n=5-6, **p<0.01 vs. all, 1-way ANOVA 
with Bonferroni correction). Error bars represent the standard error of the mean. 
Each biologically-independent sample was plated in triplicate, and the mean 
number of colonies formed per plate was considered the value for the sample.
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Stable chimerism requires one isoform of Erk. 
We next performed competitive HSC transplantation experiments to test 
HSC-autonomous, long-term Erk deletion in vivo. Competitive transplantation 
experiments rely on congenic antigens to distinguish hematopoietic source in 
transplant recipient mice. In these experiments, we employed mice with congenic 
CD45, which is a cell surface protein tyrosine phosphatase expressed on all 
leukocytes (CD45 was originally termed the “leukocyte common antigen). The 
Erk mutants are bred on a C57BL/6 background, which contains two alleles of 
the CD45.2 variant on all leukocytes. Using flow cytometry, the CD45.2 cell 
surface marker can easily be distinguished from the CD45.1 variant, which 
expresses on all leukocytes from WT B6.SJL-PtrcaPep3b/BoyJ (BoyJ) mice. 
Moreover, the first generation progeny of mice with CD45.2-expressing cells bred 
with mice with CD45.1-expressing cells (C57 x BoyJ) produce mice containing 
leukocytes with one allele each of CD45.1 and CD45.2, thus creating “double-
positive” CD45.1/2 leukocytes. By flow cytometry, these F1-derived CD45.1/2+ 
cells are also easily distinguished from CD45.1- or CD45.2-expressing cells.  
We transplanted CD45.2+ Erk mutant bone marrow cells mixed with WT 
BoyJ cells into lethally-irradiated “F1” CD45.1/2+ hosts and allowed four months 
for complete hematopoietic stem cell reconstitution of the recipients (Figure 10). 
This experiment produced chimeric mice with three sources of hematopoiesis: 
CD45.2+ Erk mutant hematopoietic stem cells, CD45.1+ WT BoyJ hematopoietic 
stem cells, and residual (~5-10%) CD45.1/2+ WT hematopoietic stem cells. After 
an assessment of chimerism at the four month time point, we injected all 
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transplant recipients with six doses, every other day, of polyIC, thus inducing 
Cre-mediated allele excision in Mx1Cre+ hematopoietic stem cell recipients. We 
then drew blood from the tail vein of live animals to progressively track overall 
peripheral blood chimerism (CD45.1+ versus CD45.2+ versus CD45.1/2+) as well 
as the production of mature marrow effector cells by chimeric source. 
This experimental design confers multiple advantages. First, based on the 
lethality of Cre induction in primary Mx1Cre+Erk1-/-Erk2flox/flox and the failure of 
DKO bone marrow precursor cells to form colonies in tissue culture, we 
hypothesized that dual Erk disruption profoundly abrogates homeostasis in 
hematopoietic and non-hematopoietic lineages. Competitive transplantation into 
WT F1 hosts not only isolates the phenotype to hematopoietic stem cells and 
their progeny, but it also provides a supportive (and easily distinguishable) 
CD45.1+ WT hematopoietic system. Thus, we were able to track mutant- and 
WT-derived long-term hematopoiesis in vivo. Moreover, we have both external 
and internal WT controls (i.e. WT BoyJ vs. Erk2flox/flox cohort as well as the WT 
BoyJ component in both cohorts). 
Four months post-transplantation, we detected no difference between the 
Erk1+/+Erk2floxflox and Erk1-/-Erk2flox/floxMx1Cre+ (essentially E1-KO) hematopoietic 
stem cell recipients (Figure 11). However, one month after Cre induction, DKO 
CD45.2+ blood cell chimerism fell to approximately half pre-induction levels. By 
six months, CD45.2+ peripheral blood chimerism in the DKO cohort dropped 
more than seven-fold, with no change detected in the control group.
Figure 10 
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Figure 10: General transplant schema. Lethally-irradiated CD45.1/2+ mice 
were transplanted with mixed CD45.2+ (Erk mutant) and CD45.1+ marrows cells 
(BoyJ WT). After four months of hematopoietic stem cell reconstitution (to 
achieve stable chimerism), mice were injected with six doses, every other day, of 
polyIC to induce Cre-mediated allele excision in Mx1Cre+ mice. Chimerism and 
lineage commitment were tracked by flow cytometry of peripheral blood extracted 
from the tail vein. Various ratios of test to competitor cells were used, as 
indicated in individual experiments.   
Figure 11 
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Figure 11: Stable hematopoiesis requires Erk. In this experiment, we mixed 
Erk mutant and WT BoyJ bone marrow cells at a 1:1 ratio and transplanted them 
into lethally-irradiated F1 mice. Four months post-transplant (-0.5 month time 
point), we detected no difference between the CD45.2+ peripheral blood 
chimerism of the Erk2flox/flox and Mx1Cre+Erk1-/-Erk2flox/flox (i.e. essentially E1-KO) 
cohorts. However, after Cre induction, the WT CD45.2+ recipients demonstrated 
stable chimerism (top) while the DKO recipients demonstrated rapid and 
progressive loss of CD45.2+ chimerism (bottom) (n=5 recipients in WT cohort and 
n=10 in DKO cohort. WT vs. DKO -0.5 month 45.2+chimerism was not significant 
by student’s t-test or 2-way ANOVA with Bonferroni correction, ***p<0.001 at one 
and six months, 2-way ANOVA with Bonferroni correction). Error bars represent 
the standard error of the mean.  
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We performed additional transplant experiments to further assess the 
hematopoietic potential of single and dually-disrupted Erk mutants. First, we 
transplanted WT BoyJ mice with E1-KO or E2-KO marrow, finding that these 
hematopoietic stem cells successfully engrafted and reconstituted major bone 
marrow lineages. Approximately six months post-transplant, we extracted 100 μL 
of peripheral blood from the tail vein of five mice in each cohort. We lysed the red 
blood cells, added lysis buffer, and standardized protein content using the BCA 
method protein assay. We then electrophoresed equivalent quantities of these 
samples, transferred the samples to a PVDF membrane, and probed with anti-
Erk1/2 antibody. We detected no Erk1 protein or Erk2 protein in the E1-KO and 
E2-KO hematopoietic stem cell recipients, respectively (Figure 12). These data 
indicate that the loss of a single Erk isoform does not preclude long-term stable 
hematopoietic reconstitution or peripheral blood production. However, we did 
detect quantitative differences in lineage commitment between WT, E1-KO, and 
E2-KO stem cell recipients, as discussed in detail below. 
To further confirm the loss-of-chimerism results in DKO HSC recipients, 
we competitively transplanted mice with Mx1Cre+Erk2fl/fl and WT BoyJ 
hematopoietic stem cells admixed at a 1:1 ratio into lethally-irradiated F1 mice. 
This experiment controls for possible loss of chimerism observed in DKO cells 
due to Cre expression (and not due specifically to the disruption of the Erk2 
isoform). Although no previous report has found the Mx1Cre construct to disrupt 
hematopoietic stem cell stability, we aimed to confirm this in the context of Erk 
disruption. Again, we allowed four months of hematopoietic reconstitution before 
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inducing Cre expression with polyIC. As hypothesized, we detected no loss in 
chimerism in the E2-KO recipients, tracked up to seven months after polyIC 
injection (Figure 13). 
We next transplanted 19 Erk mutant cells per 1 BoyJ bone marrow cell 
into primary and secondary F1 hosts. This experiment tests the hypothesis that a 
higher “dose” of DKO mutant cells could protect against the loss-of-chimerism 
phenotype. However, after four months of hematopoietic reconstitution and one 
month following Cre-induction, we found a 14-fold expansion of CD45.1+ WT 
competitor cells in the peripheral blood of CD45.2+ DKO recipients (Figure 14). 
Because the long-term persistence of lymphocytes can inflate the peripheral 
blood chimerism relative to the bone marrow chimerism, we also killed one 
mouse from each transplant cohort to assess marrow-based chimerism. 
Astonishingly, we found a 35-fold expansion in CD45.1+ WT bone marrow 
chimerism (from 2% stable peripheral blood chimerism to 76% bone marrow 
chimerism) in just one month following Cre-induction. Thus, a higher dose of 
DKO HSCs does not protect against the loss-of-chimerism phenotype. 
We then transplanted bone marrow cells from these two mice into new cohorts of 
lethally-irradiated F1 recipients, essentially testing the ability of DKO HSCs to 
engraft and self-renew. Two months following this secondary transplantation, 
peripheral blood CD45.2+ chimerism had fallen to 8% and, after six months, to 
6% (Figure 15). Thus, DKO CD45.2 chimerism fell over fifteen-fold from the initial 
94% CD45.2+ chimerism in the primary transplant recipients. In sum, these 
experiments demonstrate that dual Erk disruption results in hematopoietic stem 
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cell instability and failure to self-renew in a cell dose-independent and marrow-
autonomous manner.
Figure 12 
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Figure 12: Single Erk1-KO or Erk2-KO in HSCs is stable in long-term 
hematopoietic reconstitution. Cohorts of 9-13 BoyJ WT mice were 
transplanted with WT (Erk2flox/flox), E1-KO, or E2-KO hematopoietic stem cells. 
After more than six months after transplantation, peripheral blood was extracted 
from the tail vein, purified in RBC lysis solution, protein extracted, and the protein 
quantity standardized by BCA protein assay. Equivalent quantities were 
electrophoresed on SDS-PAGE gel, transferred to a PVDF membrane, and 
probed for Erk1 and Erk2 protein with Anti-Erk1/2 antibody. Shown are 
representative immunoblots from a total of five mice assayed in each cohort. 
Figure 13 
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Figure 13: Mx1Cre expression and loss of Erk2 do not affect HSC stability. 
Cohorts of WT F1 mice were competitively transplanted with BoyJ and Erk 
mutant marrow (Mx1Cre+Erk2flox/flox and Mx1Cre+Erk1-/-Erk2flox/flox). Cre-
expression and Erk2 allele excision was induced by polyIC injection after four 
months of hematopoietic reconstitution. Chimeric analyses shows no change in 
chimerism among E2-KO CD45.2+ peripheral white blood cells, as compared to 
the CD45.1+ fraction and to the DKO CD45.2+ white blood cells (n=10, both 
groups, p>0.05 for E2-KO %CD45.1+ cells versus %CD45.2+ cells, all time points; 
p<0.01 and p<0.001 for DKO %CD45.1+ cells versus %CD45.2+ cells, 0.5 
months and seven months, respectively, two-way ANOVA with Bonferroni 
correction). Error bars represent the standard error of the mean.
Figure 14 
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Figure 14: A high-dose of DKO HSCs does not protect against the loss-of-
chimerism phenotype. Nineteen Erk mutant bone marrow cells were 
transplanted per one WT BoyJ cell, in a total quantity of 2x106 cells per recipient. 
After four months of hematopoietic reconstitution, peripheral blood chimerism 
largely reflected this 19-to-1 ratio (i.e. ~95% CD45.2+). Two weeks after initiation 
of Cre expression, DKO CD45.2+ peripheral blood chimerism fell to 64%while the 
WT CD45.1+ fraction expanded fourteen-fold (second column). In the bone 
marrow, DKO CD45.2+ chimerism fell to 18% two weeks after initiation of Cre 
expression (third column). First two columns are representative of n=5 in WT 
group and n=10 in DKO group. Third column is from one mouse killed in each 
cohort (the same mice whose blood chimerism is shown in the second column).
Figure 15 
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Figure 15: Secondary transplantation of high-dose HSC transplant reveals 
rapid loss-of-chimerism and failure of DKO HSCs to self-renew. Bone 
marrow cells extracted from the mouse killed in each cohort from the 19-to-1 Erk-
to-WT transplant experiment were transplanted (in a non-competitive fashion) 
into new lethally-irradiated F1 recipients. DKO recipients showed a profound loss 
of CD45.2+ chimerism while WT recipients showed only minor losses, a variation 
typical of secondary transplantation experiments (n=7-9, p<0.001, %CD45.2+, 
WT versus DKO at 2 months and 6 months, 2-way ANOVA with Bonferroni 
correction).  
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Erk1/2 disruption rapidly and permanently abolishes myelopoiesis. 
Based on our initial findings from primary mutant mice and our long-term 
transplantation studies, we hypothesized that the rapid loss-of-chimerism in DKO 
transplant recipients resulted from defective myelopoiesis. However, given 
previous findings of defective lymphopoiesis in dually-disrupted Erk1/2 mutants 
(104, 105), the loss-of-chimerism phenomenon could potentially hinge on 
deficient lymphopoiesis. Indeed, mature lymphocytes (CD3+ and B220+) typically 
constitute two-thirds or more of the total peripheral blood cellularity of C57/BL6 
mice (but less than one-third of the bone marrow cellularity). To assay Erk-
dependent lymphopoiesis and myelopoiesis, in a marrow-autonomous manner, 
we examined tail vein blood of transplanted mice using ten-parameter flow 
cytometry. This protocol permitted simultaneous and comprehensive assessment 
of all major mature white blood cell surface markers as well as of the CD45.1 and 
CD45.2 congenic markers.  
By just two weeks following the polyIC regimen, we found few non-
lymphocytic (CD3-B220-) cells in the CD45.2+ fraction of DKO HSC recipients 
(Figure 16a, second column). Within these few non-lymphocytic cells, we further 
found frequency redistribution away from the expectedly preponderant CD3-
B220-Gr1+Mac1+ population, which represents circulating neutrophils (Figure 
16a, third column). Although monocyte (CD3-B220-Gr1-Mac1+) frequency 
distribution in the non-lymphoid DKO CD45.2+ fraction approximated the 
frequency in the non-lymphoid WT CD45.2+ fraction, the absolute frequency of 
DKO monocytes was severely diminished, given the overall reduction in both 
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DKO chimerism and total non-lymphoid cells. As expected from the loss in non-
lymphoid cellularity, we found a reciprocal increase in the frequency distribution 
of B220+ cells (B cells) and CD3+ cells (T cells), as a percentage of the DKO 
CD45.2+ fraction. By contrast, we found no skewing in the frequency distribution 
of CD3+CD4+CD8- (CD4 T cells) or CD3+CD4-CD8+ (CD8 T cells), as a 
percentage of the parental CD3+ population (Figure 16a, fourth column). 
We employed two strategies to quantify these results. First, we assessed 
the total lymphopoietic and myelopoietic capacities of CD45.1+ (WT BoyJ) and 
CD45.2+ (WT or DKO) marrow systems. To do so, we computed the overall 
percentage of each hematopoietic subpopulation (T cells, B cells, neutrophils, 
and monocytes) in the peripheral blood, separated by chimeric source (Figure 
16b). These analyses reveal a near-complete absence of DKO CD45.2+-derived 
circulating monocytes and neutrophils, while additionally demonstrating a 
compensatory production of myeloid cells from WT BoyJ CD45.1+ marrow. 
Moreover, these analyses revealed an absolute reduction in circulating DKO 
CD45.2+ B cells, with no change (at this time point) in circulating DKO CD45.2+ T 
cells (Figure 16c). 
Secondly, we analyzed potential skewing in lineage commitment, 
independent of the loss-of-chimerism phenotype. To accomplish this, we 
computed the ratio of the observed percentage of CD45.2+ cells within each 
subpopulation to the expected, or overall, percentage of CD45.2+ cells. For 
example, if overall CD45.2+ chimerism of a mouse is 20%, then we would expect 
approximately 20% of all circulating neutrophils to be CD45.2+, thus giving a 1.0 
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ratio for the observed-to-expected ratio. As predicted, WT myeloid populations all 
had an observed-to-expected CD45.2+ ratio close to 1.0, while DKO overall 
myeloid, monocyte, and neutrophil populations were between ten and twenty-fold 
lower than the expected 1.0 ratio (Figure 17a). Intriguingly, DKO marrow skewed 
toward circulating CD3-B220-Gr1+Mac1- cells, an undefined population of 
unknown significance. However, it should be noted that a prior publication argued 
that Mac1+ cell maturation may hinge on Mek-Erk signaling (108), suggesting 
that dual Erk disruption inhibits terminal differentiation toward Mac1+Gr1+ cells. 
Given the loss of myeloid cells, the lymphoid ratio skewed above 1.0, 
representing an abnormal persistence of DKO lymphoid cells (Figure 17b). 
In sum, these data show an absolute loss in the ability of DKO HSCs to 
produce mature monocytes and neutrophils. This myeloid deficiency is 
independent of the overall loss-in-chimerism phenotype. Finally, lymphocytes 
appeared to be less rapidly effected by Erk disruption than myelocytes, probably 
correlating with their long lifespans in the periphery.  
Figure 16a
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Figure 16: Erk disruption ablates absolute myelopoiesis in a marrow-
autonomous manner. Ten-parameter flow cytometric analyses of peripheral 
blood two months after Cre induction demonstrates ablated DKO-derived 
CD45.2+ circulating granulocytes (CD3-B220-Gr1+Mac1+) and monocytes (CD3-
B220-Gr1-Mac1+) (third column) with no distribution change in CD3+CD4+ or 
CD3+CD8+ lymphocytes (second and fourth columns) (percentages are of total 
CD45.2+ fraction) (a). Quantification of these data, by chimeric source, shows 
severe reduction in circulating DKO CD45.2+ granulocytes, monocytes, and B-
cells, with reciprocal compensation from the CD45.1+ WT BoyJ chimeric fraction. 
In the WT cohort, the granulocyte/monocyte production from CD45.1+ and 
CD45.2+ HSCs are equivalent (b-c) (n=4 and n=9, WT and DKO cohorts, 
respectively, ***p<0.001, 2-way ANOVA with Bonferroni correction). Error bars 
represent the standard error of the mean. 
Figure 17a 
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Figure 17: Erk disruption ablates absolute myelopoiesis in a chimerism-
independent manner. Standardizing CD45.2+ % of each lineage to the expected 
(overall) CD45.2+ % corrects for loss-of-chimerism and reveals potential lineage 
skewing. The dashed lines indicate the expected 1.0 ratio, whereby a chimerism 
of x% would be expected to contribute x% of the particular cell population. DKO 
CD45.2+ cells produced far fewer myeloid cells than expected, even when 
corrected for the loss-of-chimerism in these analyses. Moreover, DKO CD45.2+ 
cells abnormally skewed to undefined CD3-B220-Mac1-Gr1+ cells as well as 
increased skewing toward lymphocytes (a-b) (n=9 for WT and n=19 for DKO, 
***p<0.001, 2-way ANOVA with Bonferroni correction). Error bars represent the 
standard error of the mean.  
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Erk1/2 disruption abrogates the exponential expansion of hematopoietic 
progenitor cells. 
Based on the striking in vivo myelopoietic consequence of Erk1/2 
disruption, we assessed progenitor cell frequency and quantity in DKO bone 
marrow. Previous studies have demonstrated that hematopoietic stem and 
progenitor cells undergo an exponential expansion (149). As progenitor cells 
become more differentiated, their proliferative rate increases, peaking at the level 
of the common myeloid progenitor (CMP) and granulocyte-macrophage 
progenitor (GMP). By contrast, the near-terminally differentiated direct 
granulocytic precursors (e.g. CD3-B220-Gr1+Mac1+ cells) have a much lower 
proliferative rate, relying on the exponential expansion of precursors – the CMP 
and GMP – to replenish the rapid egress and turnover of this cell population 
(150). Table 1 shows the abbreviations, phenotypic definition, and relative 
proliferative rate of these different populations. 
In our analyses of hematopoietic stem and progenitor cell frequency and 
number, we incubated mononuclear cells with a cocktail of fluorophore-
conjugated antibodies directed against cell surface proteins marking mature 
lineage commitment (lin: CD3, CD4, CD8, B220, Gr1, Mac1, Ter119) as well as 
distinct fluorophore-conjugated antibodies directed against c-kit, Sca1, CD34, 
and FcγRII/III. The flow cytometry-based gating strategy for analyzing these 
progenitor populations, as well as representative data from WT and DKO 
samples, are shown in Figure 18a.  
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We found striking reductions in the frequency of multipotent progenitors 
(MPP: Lin-Sca1+c-Kit+), myeloid progenitors (MP: Lin-Sca1-c-Kit+), common 
myeloid progenitors (CMP: Lin-Sca1-c-Kit+CD34+FcγRII/III-/low), granulocyte-
monocyte progenitors (GMP: Lin-Sca1-c-Kit+CD34+FcγRII/III+), and 
megakaryocyte-erythroid progenitors (MEP: Lin-Sca1-c-Kit+CD34-FcγRII/III-) 
(Figure 18b-c, left/top). Adjusting for the diminished DKO cellularity per femur 
exaggerated these differences (Figure 18b-c, right/bottom), revealing a profound 
diminution of total myeloid progenitor numbers in DKO bone marrow. Dual Erk 
disruption most dramatically impacted the CMP population, which showed a near 
20-fold reduction in total number. The total GMP population was the second most 
affected, showing a six-to-seven-fold reduction compared to WT. Of note, these 
populations are the direct precursors to granulocytes and monocytes, and they 
demonstrate the highest proliferative rates among all known hematopoietic 
populations in the bone marrow. Overall, the total pool of MPs (including MEPs) 
was reduced approximately six-fold in DKO bone marrow. 
We next quantified the SLAM-LSK population (CD150+Lin-CD48-CD41-
Sca1+c-Kit), which represents long-term multi-lineage repopulating HSCs and 
constitutes about 0.007% of bone marrow cells (151). Intriguingly, in these 
analyses, we found no difference in HSC frequency between WT and DKO bone 
marrow (Figure 19a-b). These data suggest a linear relationship between HSC 
loss and overall bone marrow cellularity. Combined with the data of exponential 
loss in total myeloid progenitor number, these data implicate a proliferative defect 
at the level of the HSC.  
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Table 1. Phenotypic definitions and relative proliferative rate of 
hematopoietic stem and progenitor cells.
Figure 18a  
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Figure 18: DKO bone marrow has exponential reduction in myeloid 
progenitor number. Representative flow pictographs show progressive loss in 
the frequency of DKO multipotent progenitors (MPP, Lin-Sca1+c-Kit+), myeloid 
progenitors (MP, Lin-Sca1-c-kit+), and common myeloid progenitors (CMP, Lin-
Sca1-c-Kit+CD34+FcγRII/IIIlow), as well as deficiencies in the more committed 
megakaryocyte-erythrocyte progenitors (MEP, Lin-Sca1-c-Kit+CD34-FcγRII/III-) 
and granulocyte-macrophage progenitors (GMP, Lin-Sca1-c-Kit+FcγRII/III+) (a) 
Quantitative analyses show diminished frequency in MPPs, MPs, CMPs, MEPs, 
and GMPs (b-c, left column and top graph), with a profound diminution in the 
total number of MPs, CMPs, and GMPs (b-c, right column and bottom graph), the 
bone marrow populations that are the direct precursors of monocytes and 
granulocytes and that have the highest proliferative rate (n=7, p values derived 
from unpaired student’s t-tests; in the CMP/GMP/MEP graphs, *p<0.05, 
**p<0.01, ***p<0.001, 2-way ANOVA with Bonferroni correction). Error bars 
represent the standard error of the mean. Progenitor analyses were performed 
on two separate occasions, each with multiple biologically-independent samples.
Figure 19a
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Figure 19: DKO HSCs decline linearly with loss of DKO bone marrow 
cellularity. DKO bone marrow showed no difference in the frequency of SLAM-
LSK cells (Lin-CD48-CD41-CD150+Sca1+c-kit+), which represents the most 
phenotypically precise known definition of the long-term, multi-lineage 
repopulating hematopoietic stem cell (n=7, p value derived from an unpaired 
student’s t-test). Error bars represent the standard error of the mean. Statistical 
data are derived from one experiment with multiple biologically-independent 
replicates. HSC analyses were performed on at least three separate occasions 
with multiple biologically-independent replicates.  
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Erk1/2 disruption prevents stem cell colony formation but not BrdU incorporation. 
To further assess the consequence of Erk disruption on HSC proliferation, 
we performed multiple experiments analyzing HSC proliferative status. First, we 
injected mice with four sequential doses (2 mg/dose) of BrdU, starting two days 
after completion of the polyIC regimen (Figure 20a). We then harvested bone 
marrow, stained with cell surface markers for the HSC population, fluorophore-
conjugated anti-BrdU antibody, and propidium iodide (PI). Surprisingly, DKO 
HSCs demonstrated no difference (and, potentially, increases) in BrdU uptake 
(Figure 20b-c), implying that DKO stem cells readily synthesize DNA.  
To further assess this finding, we performed an alternative experiment 
using Hoechst (Hst) and Pyronin Y (PY) dyes. These are well-characterized dyes 
of total DNA and RNA content, respectively, and they are frequently used to 
assess the cell cycle status of hematopoietic stem and progenitor cells (152-
154). In these experiments, we found increased DNA and RNA content in DKO 
HSCs with no difference in the size and granularity of the HSC population (Figure 
21a-b). The size and granularity analysis ensures that the increase in Hst and PY 
does not correlate only to abnormal morphology secondary to Erk disruption. The 
relative increases in RNA and DNA (Hst+ and PY+) hypothetically represents an 
active cell cycle status (i.e. compartmentalization to G1, S, G2, or M). 
These data could indicate at least two scenarios: first, that DKO HSCs are 
somehow hyper-proliferating and, second, that DKO HSCs enter the cell cycle 
but do not complete mitosis. To test the counterintuitive possibility that these 
DKO HSCs were hyper-proliferating, we sorted single HSCs into methylcellulose 
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enriched with SCF, Flt3-ligand, and IL-3 (all of which stimulate HSC proliferation), 
finding no colony formation or evidence of progeny after seven to ten days in 
culture (Figure 21c). Thus, we concluded that HSC proliferation but not BrdU 
incorporation (and, thus, perhaps not G1/S entry), requires at least one Erk 
isoform.  
Figure 20a
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Figure 20: DKO HSCs incorporate BrdU. Mice were given four doses of BrdU 
(2 mg/mouse) over four days following the polyIC regimen (a). After killing, bone 
marrow cells were stained for HSC markers and BrdU and analyzed by flow 
cytometry, revealing that both WT and DKO HSCs incorporate BrdU (b). 
Quantification revealed no difference between BrdU+ DKO and WT HSCs (c) 
(n=3-7, p>0.05, student’s unpaired t-test). Error bars represent the standard error 
of the mean.  
Figure 21a
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Figure 21 DKO HSCs have increased DNA and RNA content but do not form 
colonies. Staining for HSC markers and for Pyronin Y and Hoechst one day after 
polyIC revealed increased DNA and RNA content in DKO HSCs, with no 
apparent change in overall size and granularity (a). Quantification revealed an 
increase of DKO HSCs in the cell cycle (b) (n=4-7, **p<0.01, 2-way ANOVA with 
Bonferroni correction). Single DKO SCs failed to produce any colonies or 
progeny after being sorted into 96-well plates containing methylcellulose 
enriched with serum, SCF, Flt3L, and IL-3, while no differences were detected 
among WT, E1-KO, and E2-KO HSCs (c) (n = 4-9, *p<0.05, 1-way ANOVA with 
Bonferroni correction). On all graphs, error bars represent the standard error of 
the mean.   
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Erk1/2 control HSC proliferation: additional evidence.  
We performed a number of other complementary studies to assess the 
influence of Erk activity on proliferation and survival. First, we assayed apoptosis 
using flow cytometric detection of fluorophore-conjugated Annexin V, a 
phospholipid binding protein with high affinity for exposed phosphatidylserine 
residues on the inverted membrane leaflets of cells undergoing apoptosis (155). 
In these assays, we found no consistent difference in DKO cells over E1-KO, E2-
KO, and WT cells, although DKO cells tended to show mildly higher levels 
(Figure 22a). We then probed protein samples extracted from bone marrow and 
spleen cells to assay the levels of cleaved PARP, a biochemical indicator of 
activation in pro-apoptotic pathways. In these analyses, we found no differences 
in cleaved PARP among E1-KO, E2-KO, and DKO samples (Figure 22b). 
To assess proliferation and survival ex vivo, we sorted LSK cells (MPPs) 
from the bone marrow of dozens of WT mice and performed proliferation/survival 
studies with the Mek-Erk inhibitor PD0325901. We plated equivalent numbers of 
MPPs into each well of 96-well plates containing serum and SCF. After three 
days of stimulation, we counted these cells with trypan blue, which darkly stains 
cells with disrupted membranes (i.e. apoptotic or necrotic). We performed this 
experiment on three separate occasions, finding that 100 nM of PD0325901 
reduced LSK cell proliferation between two and 10-fold (Figure 22c). By contrast, 
we did not detect consistent changes in the number of trypan blue positive cells 
per well betweenPD0325901-treated and non-treated samples. 
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We performed western blot on protein extracted from bone marrow cells to 
assess the expression level of different cyclins. Cyclin levels fluctuate as cells 
progress through the cell cycle, and their relative levels indicate the cell cycle 
status of proliferating cells (156). Generally, cyclin D increases during G1, cyclins 
E and A increase during late G1 and S-phase, and cyclin B increases during 
G2/M phases. Our protein analyses revealed severely diminished cyclin D and 
increased levels of cyclin B in DKO bone marrow cells (Figure 22d), indicating an 
abnormal compartmentalization toward later stages of the cell cycle. These data 
correlate with our findings from the BrdU- and PY/Hst-based experiments, albeit 
in the whole marrow compartment. Interestingly, E1-KO and E2-KO samples 
both demonstrated mildly diminished levels of cyclin D, although this did not 
correlate with any immediately observable phenotype. 
We also assessed cell cycle status of only the myeloid FSChiSSChi 
myeloid subset using Pyronin Y and Hoechst dyes. This experiment yielded 
similar results as our HSC cell cycle analysis, whereby the DKO samples 
demonstrated increased DNA and RNA content, indicating abnormal 
compartmentalization to S/G2/M (Figure 22e). Thus, the precise mechanism of 
abnormal proliferation in Erk-disrupted myeloid cells may be similar to Erk-
disrupted HSCs.  
Figure 22a 
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Figure 22: Additional genetic evidence that Erk’s preponderant role in the 
hematopoietic system is in the control of proliferation. Flow cytometric 
Annexin V-based detection of apoptosis in bone marrow cells revealed no 
difference between WT, E1-KO, E2-KO, and DKO samples (a) (n=3, p>0.05 for 
all comparison, one-way ANOVA with Bonferroni correction). Western blot of 
protein extracted from bone marrow cells and from the spleen showed no 
difference in cleaved PARP levels between WT, E1-KO, E2-KO, and DKO 
samples (b). Lin-Sca1+c-kit+ MPPs were FACS-sorted using admixed bone 
marrow of multiple (10-20 per experiment) wild-type mice, separated into 
triplicate wells per condition containing 10,000 cells each, pre-inhibited (one 
hour) with either 100 nM PD0325901 or vehicle only, then stimulated with 80 
ng/mL SCF and FBS for three days. PD0325901-inhibited cells showed 
consistent reductions in total proliferative output (c) (n=3 replicates, **p=0.0017, 
student’s t test). Data are representative of one experiment performed on three 
separate occasions. Cyclin level analysis was performed by western blot of 
equivalent quantities of bone marrow cells lysed in SDS-PAGE buffer, revealing 
profound diminution of cyclin D levels in DKO cells with a reciprocal increase in 
cyclin B levels (d). E1-KO and E2-KO cells also showed a moderate depression 
in cyclin D levels. Gating on the characteristic FSChiSSChi myeloid population 
revealed an increased frequency of PY+Hst+ (i.e. S/G2/M) cells (e) (n=3, 
**p<0.01, ***p<0.001, 2-way ANOVA with Bonferroni correction). In all graphs, 
error bars represent the standard error of the mean.  
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Single Erk1 or Erk2 disruption have specific long-term consequences. 
As indicated in the prior experiments, we detected few readily observable 
phenotypes in E1-KO and E2-KO bone marrow samples. We additionally 
performed experiments with bone marrow samples harboring only one allele of 
Erk: Mx1Cre+Erk1+/-Erk2flox/flox mice injected with polyIC (or, E1+/-E2-KO). These 
experiments tested the hypothesis that Erk1 and Erk2 operate in a gene dosage 
dependent manner and that by further reducing the total Erk1/2 level, a readily 
observable phenotype may emerge. However, we found no phenotype 
comparable to the DKO phenotype in the E1+/-E2-KO bone marrow cells, as 
indicated by bone marrow cellularity and colony formation (Figure 23a). Thus, the 
observed DKO phenotype – at least in terms of colony formation in tissue culture 
and maintenance of myeloid cellularity – appears to require binary and complete 
ablation of Erk1/2, without an obvious gene dose dependency. We did not test 
E1-/-E2+/- samples, although we would expect similar results. 
Intriguingly, though, we found a prominent loss of circulating lymphoid 
cells in BoyJ WT mice transplanted long-term with E2-KO hematopoietic stem 
cells (Figure 23b). Using our ten-parameter flow cytometric analyses of 
peripheral blood chimerism and lineage commitment, we found a three-fold 
reduction in the percentage of CD3+CD4+ and CD3+CD8+ T cells in E2-KO HSC 
recipients (Figure23b, top graph). The percentage of circulating CD3-B220-
Gr1+Mac1+ PMNs and CD3-B220-Gr1-Mac1+ monocytes showed a reciprocal 
increase as a frequency of peripheral blood cells (Figure 23b, bottom graph), 
while B220+ B cells showed no change as a percentage of peripheral blood cells. 
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Thus, the increase in peripheral myeloid cell frequency in E2-KO HSC recipients 
inversely correlates to the decrease in peripheral T cell frequency. 
Based on this intriguing observation, we next examined if E2-KO 
hematopoietic stem and progenitor cells possess an intrinsic ability to 
overproduce myeloid cells. While we had not detected a difference in our 
previous experiments, here we employed lower concentrations of single 
cytokines to test possible subtle consequences of Erk2 ablation. We additionally 
performed these experiments on bone marrow cells extracted from the long-term 
HSC transplant recipients, thus isolating putative phenotypes to a marrow-
autonomous etiology. However, we found no difference between WT and E2-KO 
transplanted marrow cells in their ability to form colonies on methylcellulose, at 
all tested concentrations of IL-3 and GM-CSF (Figure 23c). Of note, we also 
found no difference in total bone marrow cellularity between WT and E2-KO 
transplant recipients (data not shown). Accordingly, we concluded that the 
increased frequency of circulating myeloid cells probably results directly from the 
diminished frequency of T cells and not from an intrinsic capacity of E2-KO 
progenitor cells to overproduce myeloid cells. 
Finally, we note a mild depression in circulating myeloid cell frequency in 
the E1-KO HSC recipients, which can be appreciated in Figure 23b. In another 
set of experiments not discussed in detail here, we have found that the bone 
marrow of E1-KO mice contains reduced numbers of osteoclast-specific 
monocyte progenitors and that E1-KO cultured osteoclasts demonstrate 
impairment in multiple functional assays. These observations correspond with 
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increased bone mineral density in primary E1-KO mice and in WT mice 
transplanted with E1-KO HSCs, indicating a marrow-autonomous consequence 
of Erk1 disruption on bone physiology. Interestingly, E1-KO osteoclasts show 
diminished p90rsk phosphorylation in response to M-CSF stimulation while E2-KO 
osteoclasts have no change in their p90rsk phosphorylation levels, as compared 
to WT mice. As evidenced, myeloid/monocyte-derived osteoclasts appear to 
preponderantly depend upon Erk1 activity over Erk2 activity for functional and 
biochemical aspects. Thus, while we generally argue for Erk1 and Erk2’s singular 
dispensability in global hematopoietic stem and progenitor cell maintenance, we 
again caution against generalizing these observations toward specific effector 
cell number and function.  
Figure 23a
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Figure 23. Additional assessment of the hematopoietic consequence of 
single Erk isoform disruption. Loss of three Erk alleles produced no 
immediately discernible phenotype in experiments assaying cellularity, colony 
formation, and HSC frequency (a) (n=3-5, p values derived from student’s t-test). 
Mice transplanted more than four months with E2-KO hematopoietic stem cells 
had reduced frequency of circulating CD4+ and CD8+ T cells (b, top graph) but 
increased frequency of circulating CD3-B220- PMNs and monocytes (b, bottom 
graph), with little difference peripheral blood lineage commitment between WT 
and E1-KO HSC recipients (n=5, *p<0.05, ***p<0.001, 2-way ANOVA with 
Bonferroni correction). Bone marrow cells from WT and E2-KO HSC transplanted 
mice were extracted and assayed for myeloid colony formation using varying 
concentrations of IL-3 and GM-CSF, as indicated, but no differences were found 
(c) (n=3-4, in all comparisons p>0.05, by student’s two-tailed unpaired t-test or by 
two-way ANOVA with Bonferroni correction). In all graphs, error bars represent 
the standard error of the mean.  
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Erk disruption and Nf1-deficient hematopoiesis.  
Based on our findings here, Erk appears critical for the long-term 
maintenance of the hematopoietic system. Specifically, the rapid generation of 
myeloid cells in vivo requires at least one isoform of Erk. These data seem 
particularly relevant in light of the increased levels of phosphorylated Erk1 and 
Erk2 observed in the bone marrow cells of patients with NF1-associated juvenile 
myelomonocytic leukemia and in the cells of mice with a JMML-like 
myeloproliferative disease. 
 A recent pharmacological study found that Mek-Erk chemical inhibitors 
(e.g. CI-1040 and PD0325901) tripled survival in mice transplanted with Nf1-/- 
progenitor cells additionally transformed with a Moloney-4070A LTR virus 
(MOL4070LTR), a hybrid virus shown to preferentially induce myeloid neoplasms 
(157). In this study, Nf1-/- progenitor cells infected with MOL4070LTR produced 
an acute myelogenous leukemia (AML) hypersensitive to pharmacological Mek-
Erk inhibition. Despite the overall improvement in survival, Mek-Erk-independent 
genetic events enabled fatal leukemic progression. However, given the 
pharmacological approach, low levels of Erk phosphorylation contributing to AML 
progression could not be ruled out. Moreover, viral transformation of Nf1-/- 
progenitor cells may not accurately exemplify Mek-Erk signaling in NF1-
associated MPD. Interestingly, in another recent study, the same research group 
demonstrated that PD0325901 can virtually abrogate MPD caused by oncogenic 
Ras expression in the hematopoietic system (158) . As yet, though, the specific 
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requirement for Mek-Erk signaling in the context of Nf1-deficiency remains 
unknown. 
In an ongoing study, we are assessing the progression of Nf1-/- induced 
MPD in the context of genetically disrupted Erk1/2, testing our hypothesis that 
the diseased hematopoiesis of NF1-associated MPD requires Erk. Our laboratory 
and others have previously shown that transplantation of Nf1 deficient progenitor 
cells into WT mice is sufficient to induce a myeloproliferative disorder resembling 
human JMML (44, 45, 93, 159, 160). Accordingly, we have initiated a study to 
test Erk disruption in the context of marrow-autonomous Nf1-deficiency and 
putative MPD genesis. To do so, we have generated Nf1flox/floxErk1-/-
Erk2flox/floxMx1Cre+ mice (Nf1-/-; DKO). We have transplanted mononuclear cells 
from Nf1-/-; DKO (experimental), Nf1flox/floxMx1Cre+ (Nf1-/-; positive control), DKO, 
and E1-KO (negative controls) mice mixed at a 1:4 ratio with WT BoyJ bone 
marrow cells into the tail vein of lethally-irradiated (1100 cGy) F1 mice (n=10 
recipients per group, 40 total mice) (Figure 24). Two months following 
transplantation, we will assess initial chimerism and lineage commitment, 
followed by polyIC injection and tracking, as described above. Currently, we are 
within the two month reconstitution period. 
Initially, we expect ~20% CD45.2+ (test) and ~80% CD45.1+ (WT BoyJ) 
chimerism in all recipient groups. In the Nf1-/-; DKO group, we expect one of 
three outcomes: 1). Elimination of the CD45.2+ Nf1-/-; DKO fraction, but perhaps 
at a slower rate than in DKO only; 2). progression to MPD, with stable deletion of 
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Nf1 and Erk2, if diseased hematopoiesis does not require Erk; and 3). 
progression to MPD, with stable Nf1 deletion but continued Erk2 expression. 
Importantly, we will carefully assess Erk2 and Nf1 allele recombination efficiency 
in the CD45.2+ fraction via PCR and immunoblot, as above. If we conclude that 
NF1-associated MPD does not require Erk (in other words, MPD exists in the 
CD45.2+ fraction, Nf1 is excised, and Erk2 is excised), we will analyze Nf1-/-; 
DKO-dependent hematopoiesis in vivo and in tissue culture. To do so, we will 
assay lineage commitment in the peripheral blood of the CD45.2 (Nf1-/-; DKO) 
fraction via flow cytometry, and we will use FACS to isolate this fraction for 
molecular and functional analyses, including peripheral blood colony forming unit 
assays. We will then kill mice, isolate the CD45.2+ fraction, and perform further 
colony assays, flow cytometric phenotyping, and biochemical experiments, as 
above and described previously (148). In the scenario that NF1-associated MPD 
does not require Erk, a revelatory experiment may include next-generation RNA-
Seq using the ABI SOLiD 4 platform, comparing mRNA expression in Nf1-/-; DKO 
myeloid progenitors (e.g. lin-c-kit+ cells) to WT, Nf1-/-, and DKO myeloid 
progenitors.  
Figure 24
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Figure 24: Experimental design to assay hematopoietic Erk disruption in 
the context of Nf1 deficiency.  
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Erk and the mast cell 
Mast cell cytopoiesis requires Erk.  
To generate mast cells in vitro, we extracted bone marrow from the long 
bones of adult mice killed after the polyIC regimen, as described above. Non-
adherent bone marrow cells were passaged twice weekly for four to six weeks in 
media containing 7.5 ng/mL interleukin-3 (“MCM”), as described previously (87, 
146). Homogeneity of cultures were assessed by Giemsa/toluidine blue staining 
of typical mast cell morphology and by flow cytometric fluorophore-conjugated 
antibody-based detection of the FcεR and c-kit, cell surface markers of mast cell 
maturity, as described previously (98).  
No differences were observed in the capacity of WT, E1-KO, or E2-KO 
bone marrow cells to generate a near-homogenous population of FcεR+ and c-
kit+ cells by 4-6 weeks of MCM culture (Figure 25a), indicating normal mast cell 
differentiation from single E1-KO and E2-KO myeloid progenitor cells. We also 
tracked the expression of c-kit and FcεR+ for six weeks of multiple cultures, 
finding no substantial difference in mast cell homogeneity, differentiation, or time-
to-maturity among the single KO specimens.  
By contrast, we found that DKO bone marrow cells could not differentiate 
into mast cells in MCM, confirming a critical reciprocity for Erk1 and Erk2 in mast 
cell precursor growth and differentiation. We also repeated methylcellulose-
based colony assays using combined SCF and IL-3, two cytokines important to 
mast cell cytopoiesis. mast cell cytopoiesis. Similar to previous assays using 
mast cell cytopoiesis. Similar to our assays using mixed myeloid cytokines, no 
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DKO mast cell colonies formed (Figure 25b). We then attempted to grow colonies 
from bone marrow cells first enriched for c-kit expression using magnet-
conjugated anti-c-kit antibody beads, but we were similarly unable to grow 
colonies from DKO c-kit+ cells (data not shown).  
We found gross failure of DKO bone marrow cells to proliferate and 
adhere in liquid media (Figure 25c). In addition to MCM, we attempted to grow 
DKO bone marrow cells in liquid culture supplemented with M-CSF and RANKL, 
but these conditions yielded no proliferative or adhesive capacity. By contrast, we 
detected no differences in proliferation or adhesion among WT, E1-KO, and E2-
KO samples.  
During MCM-based culture of bone marrow cells, we tracked membrane 
leaflet inversion by flow cytometric detection of phosphatidylserine residues using 
APC-conjugated Annexin V. Generally, this loss of membrane integrity indicates 
an apoptotic cell. In these assays, we found little difference in the frequency of 
apoptotic cells between WT, E1-KO, E2-KO, and DKO bone marrow cells on the 
first day of culture. However, further culture of DKO bone marrow cells revealed 
a rapid induction of apoptosis and, by four weeks, only scant and apoptotic or 
necrotic (Annexin V and propidium iodide double positive) cells remained (Figure 
25d).  
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Figure 25: Mast cell cytopoiesis, colony formation, and bone marrow cell 
growth require Erk. Non-adherent bone marrow cells were passaged twice 
weekly for four weeks in IMDM containing 10% FBS and 7.5 ng/mL IL-3 (MCM), 
revealing a critical requirement for either Erk1 or Erk2 in mast cell cytopoiesis, as 
assessed by flow cytometric detection of c-kit and FcƐRI, cell surface markers of 
mast cell maturity (a). No differences were detected in mast cell cytopoiesis at 
four weeks between E1-KO, E2-KO, and WT cultures. Data are representative of 
at least six independent cultures for each genotype. DKO bone marrow cells 
produced few colonies in methylcellulose media supplemented with IL-3 and M-
CSF (n=3-4, ***p<0.001, DKO vs. all, one-way ANOVA with Bonferroni 
correction). Crystal violet staining demonstrates that DKO bone marrow cells 
have a dramatically diminished capacity to adhere and proliferate in liquid 
culture, with no differences detected among E1-KO, E2-KO, and WT cultures (c). 
In these photographs, adherent cells were principally (although not exclusively) 
monocyte/macrophages. Data are representative of at least six independent 
cultures for each genotype. Apoptosis was assessed by flow cytometric detection 
of phosphatidylserine by APC-conjugated Annexin V, revealing a rapid and 
persistent induction of cell death in DKO bone marrow cells grown in liquid 
culture (n=2-3 at time points with statistical analyses, ****p<0.0001, DKO vs. all, 
two-way ANOVA with Bonferroni correction).  
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Chemical Mek-Erk inhibition in mast cells. 
As our data indicate that mast cell cytopoiesis requires one isoform of Erk, 
we have devised alternative chemical and genetic approaches to study dual Erk 
inhibition in mature mast cells. First, we have treated cultured mast cells with 
PD0325901, a small molecule inhibitor of Mek1/2 that prevents the 
phosphorylation and activation of Erk1/2. Compared to previous generation Mek-
Erk inhibitors (e.g. PD98059, U0126, CI-1040), PD0325901 exhibits greater 
selectivity, potency, and oral bioavailability, thus making the molecule a more 
suitable research tool and a potentially effective pharmacological agent (Figure 
26) (113, 161, 162). Several investigations have found that PD0325901 can 
inhibit cancer cell growth at nanomolar to sub-nanomolar concentrations in vitro 
(163-167). Based on these findings, investigators have used PD0325901 to 
attenuate the progression and severity of certain murine-modeled cancers, 
including glioma, hepatocellular carcinoma, thyroid cancer, prostate cancer, a 
virally-induced acute myelogenous leukemia, and an oncogenic Ras-dependent 
leukemia (158, 163, 166-168). Moreover, two phase II clinical trials have 
assessed PD0325901 efficacy in the treatment of metastatic, chemotherapy 
refractory cancers (169, 170), although few clinical studies have examined 
PD0325901’s efficacy in less-progressed neoplasia. Likewise, few studies have 
examined PD0325901 in the context of primary, non-transformed cultured cells.  
  
Figure 26 
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Figure 26: PD0325901 is a new generation, pharmacological grade Mek-Erk 
inhibitor. PD98059 (left) is the best-characterized and most widely-used inhibitor 
of Mek phosphorylative activity on Erk1/2. However, PD98059 has poor solubility, 
a non-pharmacological IC50 (10-100 μM in most cell types), a tendency to 
crystalize, and multiple off-target effects. Structural modifications in the PD98059 
led to the development of CI-1040, the first Mek-Erk inhibitor to be used in clinical 
trials (middle). Further modification of CI-1040 led to the development of 
PD0325901 (N-((R)-2,3-dihydroxy-propoxy)-3,4-diXuoro-2-(2-Xuoro-4-iodo-
phenylamino)-benzamide), which demonstrates the greatest potency and 
metabolic stability of the small molecule Mek-Erk inhibitors (right).  
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PD0325901 inhibits SCF-mediated Erk1/2 phosphorylation. 
Because PD0325901 is a relatively new Mek-Erk inhibitor found in far 
fewer published studies than its predecessors (e.g. PD98059, U0126), we first 
aimed to establish its potency, efficacy, and selectivity in inhibiting Erk1/2 
phosphorylation in SCF-stimulated primary mast cells. To do so, we pre-
incubated growth factor deprived mast cells with varying concentrations of 
PD0325901, stimulated the cells for five minutes with SCF, extracted protein, and 
subsequently performed western blots to assess the phosphorylation level of 
Erk1/2 and other kinases. We chose five minutes as the endpoint because our 
prior experiments have shown that phospho-Erk1/2 levels peak between two and 
five minutes following SCF stimulation. In other experiments discussed below, we 
assessed other time points following SCF-stimulation. 
We found that 25 nM of PD0325901 reduced the phosphorylation level of 
Erk1/2 in SCF-stimulated mast cells by nearly one-half the phosphorylation level 
of mast cells pre-treated with vehicle only (Figure 27a). At over 200 nM 
PD0325901, Erk1/2 phosphorylation could barely be detected. Moreover, the 
phosphorylation level of p90rsk, which is a putatively specific measure of Erk 
kinase activity, directly correlated with the phosphorylation level of Erk1/2 was 
effectively inhibited by PD0325901 in the SCF-stimulated mast cell. 
At this five minute time point, we detected a high degree of variability in 
the level of phospho-AktS473. As we have noted in other experiments, Akt 
phosphorylation secondary to SCF-stimulation does not demonstrate strictly 
predictable time-dependency that SCF-mediated Erk1/2 phosphorylation does. 
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Most importantly, though, the variable level of phospho-Akt did not correlate with 
increasing concentrations of PD0325901. Because phospho-Akt is a sensitive 
measure of PI-3K activation, we concluded that up to 400 nM PD0325901 does 
not inhibit PI-3K, at least in a dose-dependent manner (Further time points and 
affects are discussed later). We also found that up to 400 nM PD0325901 does 
not inhibit phosphorylation of GSK3βS9 at five minutes, a direct target of activated 
Akt. However, as discussed later, PD0325901 appears to modulate the 
phosphorylation status of Akt andGSK3β at later time points through potentially 
discrete mechanisms. 
The IC50 for PD0325901’s inhibition of Erk1/2 phosphorylation in SCF-
stimulated mast cells was 37 nM (Figure 27b). The compound’s maximal 
inhibition of Erk1/2 phosphorylation occurred at 200 to 400 nM. The 
phosphorylation level of p90rsk directly correlated with Erk1/2 phosphorylation, 
while AktS473 phosphorylation did not correlate with PD0325901 concentration. 
These parameters largely reflect findings of high selectivity, high potency, and 
sub-micromolar efficacy in prior publications concerning the use of PD0325901 in 
various transformed and non-transformed cell types (113, 163-165, 171-175). 
We have concluded that PD0325901 exhibits potency and selectivity for 
Mek-Erk inhibition, preliminarily serving as a valuable tool for the study of Erk-
dependent, SCF-mediated mast cell function. Accordingly, throughout the 
following experiments, we studied the role of Erk1 and Erk2 in SCF-mediated 
mast cell physiology and biochemistry using WT, E1-KO, E2-KO, and 
PD0325901-treated WT primary mast cells.
Figure 27a
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Figure 27: PD0325901 inhibits Erk1/2 phosphorylation. Mast cells were 
deprived of growth factors overnight, resuspended to a standard concentration, 
pre-incubated with the indicated concentrations of PD0325901, and stimulated 
with SCF. After five minutes, cell aliquots were briefly centrifuged at 4°C and 
resuspended in SDS-PAGE buffer. After electrophoresis and transfer to PVDF 
membrane, samples were probed with the indicated antibodies. PD0325901 
efficiently inhibited Erk1/2 phosphorylation and p90rsk phosphorylation (a 
putatively specific indicator of Erk kinase activity) (a). PD0325901 did not appear 
to modulate levels of phospho-AktS473 or phospho-GSK3βS9 in a dose-
dependent manner at this time point. The three parameter logarithmic 
regressions demonstrate a biochemical IC50 of 30-35 nM as well as no 
relationship between PD0325901 concentration and Akt phosphorylation status 
(b). To build the dose-inhibition curve, the ratio of phosphorylated to total at the 
non-stimulated time point was subtracted from all points. (e.g.“0.0” represents 
density values from protein samples extracted from non-stimulated cells).
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Single Erk isoforms are dispensable for SCF-mediated mast cell proliferation. 
We performed multiple experiments using different techniques to assess 
the consequence of Erk1 disruption, Erk2 disruption, and PD0325901-treatment 
on SCF-mediated mast cell proliferation. These methods included total 
proliferative output (fold change in culture size, starting from a defined cell 
number), radioactive thymidine incorporation, and MTT-based assessment of 
metabolic activity, which can serve as a high-throughput surrogate for 
hemcytometer-based assays of total proliferative output. 
First, we assessed whether single Erk disruption altered mast cell 
proliferation. Mast cells were deprived of growth factors overnight, plated in one 
mL IMDM at 250,000 cells per well in duplicate in a 24-well plate, and stimulated 
with 10% FBS and 25 ng/mL SCF. After 72 hours at 37°C, cells were stained with 
trypan blue (a negative marker for cell viability) and enumerated using an 
inverted light microscope.  
In this experiment, we found no difference in the fold change of cell 
number between WT, E1-KO, and E2-KO samples, all of which approximately 
doubled in number during the course of the experiment (Figure 28). We repeated 
these experiments multiple times as well as by using MTT-based assays (data 
not shown), again finding no difference in the total proliferative capacity of SCF-
stimulated WT, E1-KO, and E2-KO mast cells. Of note, we trialed various time 
points (24 to 96 hours) and concentrations of SCF (10 to 100 ng/mL), attempting 
to uncover dose- or time-dependency of putative consequences of single Erk 
isoform disruption. Throughout these experiments, though, we were unable to 
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identify any difference between SCF-mediated proliferation in WT, E1-KO, and 
E2-KO mast cells. As with HSC stability, single Erk isoforms appear dispensable 
for the total proliferative output of SCF-stimulated primary cultured murine mast 
cells. 
Based on the biochemical studies of PD0325901 described above, we 
next examined SCF-mediated mast cell proliferation using increasing 
concentrations of PD0325901. This hemcytometer-based experiment was 
performed in a similar manner to the proliferation experiment described above, 
except that cells were incubated with 100 nM PD0325901 or vehicle alone for 
approximately one hour prior to stimulation with FBS/SCF.  
In this experiment, we found a clear dose-response between PD0325901 
inhibition and reduction in SCF-mediated mast cell proliferation, similar to our 
biochemical experiments assaying Erk1/2 phosphorylation. Intriguingly, 100 nM 
of drug abrogated proliferation in these cells (Figure 29). Due to the closeness in 
PD0325901 dosage required to inhibit SCF-mediated Mek-Erk phosphorylation 
and to abrogate SCF-mediated proliferation, our initial data suggest that SCF-
mediated mast cell proliferation largely requires Erk kinase activity.  
Of note, we did not observe substantially increased trypan blue uptake in 
cells treated with 12.5 to 100 nM of PD0325901, indicating that these cells were 
not undergoing apoptosis. These observations indicate that 100 nM PD0325901 
principally halts proliferation but does not induce cytotoxicity or apoptosis.  
To further explore the mechanics of Erk-dependent SCF-mediated mast 
cell proliferation, we performed 3H-thymidine incorporation assays. These 
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experiments quantitate DNA synthesis by detection of newly-incorporated, 
radioactively-labeled thymidine bases. As a note of distinction, these assays 
measure S-phase entry from G0 or G1, not total proliferative output. 
In our initial experiments assaying thymidine incorporation after SCF-
stimulation, we aimed to characterize the kinetics of the initiation of DNA 
synthesis in mast cells deprived of growth factors overnight. We standardized cell 
concentrations and plated 50,000 per well in a 96-well plate, incubated the cells 
with 100 nM PD0325901, and subsequently stimulated them with 10% FBS and 
80 ng/mL SCF supplemented with 1 μCi 3H-thymidine. Starting at two hours after 
stimulation and at multiple time points following, we froze identically established 
96-well plates at -20°C until the conclusion of the experiment, at which time we 
assayed thymidine incorporation with a scintillation counter.  
We found that FBS/SCF-stimulated mast cells incorporated almost no 3H-
thymidine in the first ten hours following stimulation (Figure 29b, top graph). This 
G1 lag phase was followed by a slow but detectable rise in thymidine 
incorporation between 12 and 16 hours. Thymidine incorporation then rapidly 
accelerated between 20 and 28 hours following stimulation.  
Intriguingly, 100 nM PD0325901 appeared to not affect the quantity of 
thymidine incorporation during this early induction phase. Of note, in these initial 
experiments we assayed only pooled samples in replicate (thus precluding our 
ability to perform biologically-independent statistical analysis).  
Based on these preliminary findings, we performed a similar experiment 
under different timing conditions. Here, we stimulated growth factor-deprived 
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mast cells with FBS/SCF for sixteen hours and subsequently added 3H-
thymidine, thus reducing unnecessary exposure to radiation, which could 
possibly modulate normal cellular proliferation (176). In this experiment, we again 
found little thymidine incorporation two and four hours following its addition 
(representing hours 18 and 20 of total FBS/FBS stimulation) (Figure 29b, bottom 
graph). However, FBS/SCF-stimulated mast cells incorporated the largest 
quantity of thymidine between approximately 28 and 36 hours. This increased 
rate then plateaued by 48 hours. Moreover, 100 nM PD0325901 dramatically 
reduced the large increase in thymidine incorporation observed between 28 and 
36 hours in FBS/SCF stimulated WT, E1-KO, and E2-KO mast cells.  
Overall, these experiments indicated that the transition to S-phase after 
growth factor deprivation requires at least twelve hours of FBS/SCF-stimulation. 
Additionally, they demonstrated that maximal DNA synthesis occurs between 28 
and 36 hours. 
Using these observations, we assessed the dependency of SCF-mediated 
mast cell thymidine incorporation on increasing doses of PD0325901. We 
performed these experiments similar to those described above, adding 3H-
thymidine 16 hours after stimulation with 10% FBS and 80 ng/mL SCF. The 
plates were placed at -80°C at 24 and 48 hours (total) following stimulation. Here, 
we found no statistical difference in the sensitivity of WT, E1-KO, and E2-KO to 
increasing concentrations of PD0325901 (Figure 29c). While the computed IC50 
values for maximal inhibition of thymidine incorporation for WT, E1-KO, and E2-
KO cells were 31 nM, 19 nM, and 51 nM, respectively, at 24 hours and 65 nM, 25 
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nM, and 26 nM, respectively, for 48 hours (both with broad 95% confidence 
intervals), 400 nM of PD0325901 failed to inhibit thymidine incorporation to less 
than 20% of the untreated value in both WT and E2-KO cells. Intriguingly, 400 
nM of PD0325901 diminished thymidine incorporation in E1-KO cells to 5% of 
their untreated values, and, by using a student’s unpaired t-test, these 
differences between E1-KO versus WT and E2-KO cells were significant at 
p<0.05. However, they were not significant in the appropriately applied 2-way 
ANOVA with Bonferroni correction. Whether or not E1-KO cells are indeed more 
sensitive to PD0325901 inhibition requires further examination.
Figure 28 
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Figure 28. E1-KO, E2-KO, and WT mast cells show no difference in SCF-
mediated proliferation. Primary cultured mast cells were deprived of IL-3 and 
FBS overnight and resuspended at 250,000 per mL in IMDM. One mL of cells per 
condition were plated in duplicate into each well of a 24-well plate. Cells were 
stimulated with 25 ng/mL SCF and 10% FBS and allowed to grow for 72 hours at 
37°C. Cells were then enumerated by hemcytometer using trypan blue exclusion 
on an inverted light microscope. Cell viability was comparable among all cultures. 
The mean of duplicate cultures were considered the value for each biologically-
independent sample (n=3). P values were not significant by either one-way 
ANOVA with Bonferroni correction or by student’s unpaired t-tests. Error bars 
represent the standard error of the mean. These data represent at least two 
experiments performed on separate occasions using multiple biologically-
independent samples per experiment.
Figure 29a 
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Figure 29: Quantitative effects of genetic and chemical Mek-Erk inhibition 
on proliferation and thymidine incorporation. To establish the efficacy of 
PD0325901 in inhibiting total proliferative output, experiments were performed as 
described in Figure 28, but mast cells were first incubated for one hour with 
increasing concentrations of PD0325901 or with vehicle only before SCF/FBS 
stimulation. 100 nM of PD0325901 completely inhibited total mast cell 
proliferative output (a) (at 100 nM, mean number was 91% of input, n=3, p<0.05 
for 100 nM versus 0, 12.5, and 25 nM by student’s unpaired t-test). Error bars 
represent the standard error of the mean. 3H-thymidine incorporation 
experiments were performed on 50,000 cells per well in 100 μL IMDM in 96-well 
plates, stimulated with 10% FBS and 80 ng/mL SCF. In initial experiments, we 
determined that growth factor-deprived mast cells require approximately 16 hours 
to begin rapidly incorporated of thymidine while finding little evidence of 
differences between E1-KO, E2-KO, WT cells (b) (pooled samples performed in 
replicate; no statistical analyses performed). By titrating PD0325901 dose, we 
found that IC50 values for all three genotypes for inhibiting thymidine 
incorporation are less than 100 nM, with no significant difference detected 
between WT, E1-KO, and E2-KO cells (c) (n=3 for each genotype, all 
comparisons not significant via 2-way ANOVA with Bonferroni correction). By 
less rigorous statistical testing, E1-KO cells had a significantly increased 
sensitivity to 400 nM PD0325901 (p<0.05 versus WT and E2-KO, student’s 
unpaired t-test). Error bars represent the standard error of the mean. In a and c, 
dotted lines indicate a three-parameter logarithmic non-linear regression.
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 PD0325901 reduces BrdU incorporation in SCF-stimulated mast cells. 
From our experiments above, we concluded that 100 nM PD0325901 can 
completely inhibit the generation of new mast cell progeny following SCF-
stimulation (Figure 29a). However, we still detected thymidine incorporation in 
SCF-stimulated mast cells up to 400 nM PD0325901, implying that some cells 
had begun S-phase despite the Mek-Erk inhibition. We considered that similar to 
our HSC studies, some PD0325901-inhibited mast cells may enter S-phase but 
ultimately not divide. Alternatively, PD0325901-inhibited mast cells may begin 
synthesizing DNA but subsequently fail to complete S-phase.  
To further explore the cell cycle kinetics of PD0325901-inhibited mast 
cells, we performed BrdU pulse-chase experiments. Here, mast cells were 
stimulated with SCF and FBS for 24 hours, pulsed with BrdU for 2 hours, and the 
BrdU washed out. Some cultures were then re-treated with PD0325901, testing 
continued Mek-Erk inhibition on cells which had already begun the cell cycle (i.e. 
those cells detected as BrdU+). We stopped different cultures at three, six, and 
twelve hours following the BrdU washout, predicting that these would be 
sufficient times to detect a full cycle of cell division in BrdU-labeled cells.  
In our preliminary experiment, we found that 100 nM PD0325901 reduced 
the frequency of cells incorporating BrdU and, thus, entering S-phase, by 
approximately half (Figure 30, left column). After washing out the BrdU and 
reapplying PD0325901, we found no additional reduction in the frequency of cells 
that completed the cell cycle, as indicated by the shift in 7-AAD staining of total 
nuclear material (Figure 30, second and third columns). Therefore, once these 
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SCF-stimulated mast cells incorporated BrdU, 100 nM PD0325901 appeared 
incapable of preventing completion of mitosis.  
These chemical findings contrast our genetic findings in HSCs in vivo, 
whereby DKO HSCs incorporated BrdU and had increased nuclear material but 
failed to proliferate. Of critical note, though, our mast cell proliferation 
experiments rely on a single cytokine (SCF) as well as chemical inhibitors in 
vitro. To further assay this phenomenon, we are now developing more precise 
methods, including genetic ablation of Erk1/2 in primary mature mast cells.
Figure 30 
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Figure 30: PD032901 reduces BrdU incorporation but not mitosis in SCF-
stimulated mast cells. Mast cells were deprived of growth factors overnight and 
stimulated with SCF and FBS. Some cultures were pre-incubated with 100 nM 
PD0325901. After 24 hours at 37°C, cultures were pulsed with BrdU for two 
hours and the BrdU subsequently washed out. PD0325901 was then re-
introduced to some cultures. While PD0325901 reduced the frequency of cells 
incorporating BrdU (left column), it did not prevent cells from completing mitosis 
(middle and right columns). This is non-quantitative and representative of only 
one experiment. 
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Erk negatively regulates SCF-mediated mast cell cytokine production. 
Mast cells modulate inflammation via the production and secretion of 
multiple pro- and anti-inflammatory cytokines. To obtain a general assessment of 
which cytokines SCF-stimulated mast cells elaborate, we first performed a broad-
based cytokine array to screen 40 possible candidates. This experiment relies on 
membranes pre-coated with specific antibodies which are subsequently 
incubated with supernatant from SCF-stimulated mast cells (i.e. mast cell 
conditioned media). Mast cells were first deprived of growth factors overnight 
then stimulated with SCF (only) for six hours. The conditioned media was then 
harvested for protein assays. 
In these experiments, SCF stimulation induced the release of MCP-1 (JE), 
MIP-1α, IL-6, TNF-α, M-CSF, GM-CSF, and IL-13 (Figure 31). All of these 
cytokines serve generally inflammatory roles, including the stimulation and 
recruitment of macrophages, monocytes, and other myeloid cells (e.g. M-CSF, 
MIP-1α)(177, 178). Interestingly, SCF stimulation reduced the secretion of IL-16, 
a cytokine which principally modulates T cell function. We found that WT and 
Nf1+/- mast cell secreted a similar panel of cytokines, with the exception that 
Nf1+/- mast cells secreted an increased amount compared to WT mast cells. Of 
the total 40 proteins tested, only those cytokines with an appreciable change 
compared to samples from non-stimulated mast cells are shown. 
Using the data derived from this qualitative screen, we next performed a 
quantitative multiplex assay to determine the consequence of single Erk genetic 
inhibition, of PD0325901 treatment, and of increasing SCF concentrations on 
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cytokine secretion in a quantitative fashion. Conditioned media was prepared 
similarly to the cytokine array experiment. Following supernatant isolation, 
samples were processed with a multiplex kit including analytes for M-CSF, TNF-
α, MCP-1, MIP-1α, MIP-1β, G-CSF, GM-CSF, IL-10, IL-13, and IL-6.  
Largely, we found no difference among E1-KO, E2-KO, and WT samples 
in their capacity to generate increasing levels of the six cytokines in response to 
SCF stimulation (Figure 32a). If anything, single Erk disruption tended to 
increase the quantity of cytokine produced and secreted (although, through this 
experiment’s sample size, the variability of cytokine levels produced from 
biologically-independent samples was too great to detect any differences). As an 
intriguing parallel to this possible increase in cytokine production from single KO 
mast cells, pre-incubation with PD0325901 followed by SCF-stimulation 
potentiated maximal cytokine secretion in a dose-dependent manner. These data 
are statistically presented for the 100 ng/mL SCF stimulation condition (Figure 
32b), revealing that PD0325901 increased the quantity of MCP-1, MIP-1α, MIP-
1β, IL-13, andIL-6 in mast cell conditioned media. Only TNF-α secretion did not 
change with PD0325901 treatment. Potentially, then, Erk negatively regulates the 
production of multiple cytokines in the SCF-stimulated mast cell. The implications 
of this, as well as ongoing experiments to further elucidate this observation, are 
presented in the Discussion.  
Figure 31 
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Figure 31: Cytokine array delineates multiple cytokines secreted from SCF-
stimulated primary mast cells. Mast cells were derived of growth factors 
overnight and stimulated for six hours with 50 ng/mL SCF at 37°C. The 
supernatants were harvested and assayed by a mouse-specific cytokine array 
panel, which detects up to 40 individual proteins using immunological methods. 
As can be seen on the exposed immunoblot membranes (bottom), each cytokine 
antibody is spotted in duplicate (the three dense duplicates in the upper left, right 
and lower left corner are positive controls; lower right is negative control). Using 
arbitrary density units, all spots were quantified and graphed, revealing several 
cytokines induced by SCF stimulation. Only those cytokines with an appreciable 
change between the stimulated and non-stimulated state are shown. Similar 
experiments were performed on two other occasions.  
Figure 32a
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Figure 32: Quantitative assessment of Erk disruption and PD0325901 
treatment on mast cell cytokine production. Mast cell supernatant was 
produced according to the protocol described for the cytokine array panel, 
although, in this experiment, cells were pre-treated with 100 nM PD0325901 and 
stimulated with increasing concentrations of SCF. Few differences were detected 
between E1-KO, E2-KO, and WT samples. However, PD0325901 treatment 
potentiated cytokine production (a) (n=5 for WT, 4 for E1-KO, 2 for E2-KO, and 3 
for PD0325901-treated). Error bars represent the standard error of the mean. 
The lines indicate a three-parameter logarithmic regression. Detailed analyses 
comparing the fold change over the mean WT value for each cytokine at 100 
ng/mL SCF revealed that all analyzed cytokines except TNF-α were potentiated 
by PD0325901 treatment (b) (*p<0.05, ***p<0.001, ****p<0.0001, as compared to 
WT, 2-way ANOVA with Bonferroni correction). E2-KO cells also tended to have 
increased cytokine production, with the value for IL-13 at 100 ng/mL significant at 
a confidence of p<0.05. All other comparisons to WT were not significant. For 
statistical purposes, each individual WT value was compared to the aggregate 
WT mean for each cytokine. Error bars represent the standard error of the mean.
176 
Erk-dependent biochemical alterations in the mast cell. 
To understand the mechanisms of how single KO mast cells functionally 
compensate for the loss of the complementary Erk isoform, we performed 
various biochemical experiments on SCF-stimulated mast cells. As foundation, in 
total bone marrow cells we regularly observed mildly increased Erk1 levels in E2-
KO cells, as can be seen in Figure 3c and as emphasized in Figure 33a. 
However, we did not detect a reciprocal increase in Erk2 levels in E1-KO cells (in 
either total bone marrow cells or mature mast cells). These data may indicate a 
preponderant biochemical importance for Erk2 in marrow and mast cell function, 
although more precise studies are needed in specific cell lineages. 
Intriguingly, and perhaps in complement to the above observations, we 
found that total Erk2 levels decreased in some E1-KO mast cells. However, the 
Erk2 phosphorylation level subsequent to SCF-stimulation approximated WT 
samples (Figure 33b). Other reports have suggested that loss of Erk1 can lead to 
hyperphosphorylation of Erk2 and, subsequently, increased biological activity in 
Erk-mediated functions (124, 128, 179). Hypothetically, then, disruption of Erk1 
increases the availability of Erk2 to phosphorylation by Mek1/2. If true, this 
observation in cultured mast cells may indicate that the E1-KO mast cell down-
regulates total Erk2 protein level to prevent abnormal hyperactivation of Erk2. 
These conjectures are supported by the observation of few, if any, functional 
differences between SCF-stimulated WT, E1-KO, and E2-KO mast cells. It 
should be noted that we observed this down-regulation of Erk2 only under 
specific conditions (and especially in older culture age mast cells).  
Figure 33a
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Figure 33: Biochemical consequence of single Erk disruption on the level 
and phosphorylation status of the complementary isoform. In bone marrow 
cells, we consistently observed a mild increase in the level of Erk1 protein in E2-
KO samples (a). We did not detect increased Erk2 levels in protein from E1-KO 
samples. This phenomenon can also be appreciated in Figure 3c. In mature 
primary mast cells, E1-KO cells downregulate Erk2 levels as the cells age (b). 
However, the total quantity of phosphorylated Erk2 approximates WT levels 
following SCF-stimulation.  
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As we considered that E1-KO and E2-KO mast cells may develop 
irregularities in PI-3K-directed pathways, we next examined phosphorylation 
events in the canonical PI-3K pathway. We additionally assayed SCF-mediated 
regulation of β-catenin, a signaling mechanism as yet not described for primary 
cultured mast cells. Several reports instigated our interest in β-catenin signaling 
in the mast cell. These reports demonstrated that PI-3K pathways can influence 
β-catenin translocation, that Erk1/2 kinase activity can directly influence β-
catenin levels through the phosphorylation of GSK3β and p90rsk, and that SCF-
stimulated mast cell-like leukemia lines demonstrate nuclear β-catenin in vitro 
(180-182). Based on these publications, we postulated that β-catenin activity may 
be important to SCF-mediated mast cell function and that Erk may influence this 
activity. 
Indeed, we found that SCF induces the phosphorylation of β-catenin at 
serine 552 and serine 675 (Figure 34). These findings corresponded with potent 
phosphorylation of Akt at serine 473 and GSK3β at serine 9, a signaling axis 
which can modulate β-catenin stability and activity in the context of co-activated 
receptor tyrosine kinase and Wnt/Frizzled pathways. In this schema, PI-3K 
activated Akt phosphorylates and inactivates GSK3β, which, along with other 
events, permits β-catenin to escape sequestration and marking for proteasomal 
degradation by ubiquitin ligases. Disinhibited β-catenin can then undergo 
phosphorylation, translocate to the nucleus, and activate mitogenic transcription 
factors (183). 
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Intriguingly, PD0325901 inhibited the upregulation of β-catenin in SCF-
stimulated primary mast cells (Figure 35a). We typically observed maximal β-
catenin levels at thirty minutes to one hour following stimulation with FBS/SCF. 
At one hour, PD0325901 reduced this level to near non-stimulated levels. To 
assess the sub-cellular localization of β-catenin, we imaged mast cells via 
deconvolution microscopy, finding that PD0325901 could inhibit the SCF-
stimulated translocation of β-catenin to the nucleus (Figure 35b). While 
compelling, these findings need further validation and quantification, especially 
through immunoblot of specific cell fractions under varying conditions (e.g. 
nucleus, membrane, organelles with/without FBS at various time points). 
Of note, we did not detect a change in phospho-Akt levels at thirty 
minutes, one hour, and three hours following SCF-stimulation and PD0325901-
inhibition (Figure 35a). However, phospho-Akt increased substantially at six 
hours during PD0325901 treatment. While the phosphorylation of GSK3β at 
serine 9 largely followed the levels of phospho-Akt at thirty minutes and six 
hours, PD0325901 treatment mildly depressed phospho-GSK3βS9 at one and 
three hours. Interestingly, Hu et al reported that Erk kinase activity directly primes 
GSK3β for additional phosphorylation at its serine 9 by p90rsk (which is also 
dependent on Erk activity) (183), leading us to suspect that Mek-Erk directly 
modulates GSK3βS9 phosphorylation and β-catenin levels. Although we have 
ongoing experiments to assess interactions between Erk, GSK3β, and p90rsk, 
we have not as yet co-immunoprecipitated these proteins in SCF-stimulated 
primary mast cells, as Hu et al did in immortalized cell lines (183). In our 
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alternate strategy, we are using deconvolution microscopy to identify possible co-
localizations between the three molecules during SCF/FBS stimulation.  
Finally, we have taken a particular interest in the PD0325901-mediated 
potentiation of phospho-Akt at six hours. As found in the Discussion, we suggest 
potential mechanisms by which this potentiation of phospho-Akt may explain 
increased cytokine production in PD0325901-inhibited cells. We also delineate 
several experiments to further explore these hypotheses. 
We next assessed β-catenin levels in E1-KO and E2-KO mast cells, 
finding great variability in the basal level of β-catenin in the mutants as compared 
to WT samples (Figure 35c). In the experiment  shown, β-catenin levels in single 
Erk KOs do not follow FBS/SCF-stimulation but rather persist throughout the 
stimulation period. We have obtained similar results in analyses of E1-KO mast 
cells by confocal microscopy (data not shown), and we are continuing to assess 
the specifics of this β-catenin deregulation in single Erk-KO mast cells. As now, 
our data suggest that single Erk-KO mast cells compensate biochemically by 
upregulating β-catenin levels, perhaps through aberrant phosphorylation of 
AktS473. However, our data indicate that the short-term induction of β-catenin 
requires at least some measure of Mek-Erk activity. To address these intricacies, 
we are examining SCF-stimulated mast cells lacking β-catenin 
(Mx1Cre+Ctnnb1flox/flox) as well as further exploring biochemical alterations in 
mast cells genetically disrupted for Erk1/2, as described below.  
Figure 34
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Figure 34: SCF induces the phosphorylation of β-catenin. Mast cells were 
deprived of growth factors overnight, standardized by concentration, and 
stimulated with recombinant murine SCF. Proteins were extracted in SDS-PAGE 
buffer, electrophoresed, and transferred to a PVDF membrane for subsequent 
analysis by immunoblotting. The phosphorylation of β-catenin’s serine residue 
552 was readily observed after five minutes and peaked at thirty minutes 
following stimulation. Phosphorylation of serine residue 675 occurred more 
slowly but also peaked at thirty minutes following stimulation. These 
phosphorylation events correlated with the activating phosphorylation of AktS473 
and the inhibitory phosphorylation of GSK3βS9 which, in canonical β-catenin 
signaling, precedes β-catenin activation and nuclear translocation.  
Figure 35a 
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Figure 35: β-catenin is upregulated, phosphorylated, and translocates to 
the nucleus in SCF-stimulated mast cells in a Mek-Erk-dependent manner. 
Mast cells were deprived of IL-3 overnight, suspended to a standard 
concentration, and stimulated with FBS/SCF, with or without pre-incubation in100 
nM PD0325901. PD0325901 prevented the upregulation of β-catenin, as seen at 
one hour, three hours, and six hours in non-treated cells (a). PD0325901 also 
diminished the level of phospho-GSK3βS9 while potentiating the level of phospho-
AktS473 at six hours following SCF-stimulation. Similar immunoblots were 
performed on at least three separate occasions. Stimulated mast cells were fixed 
and processed for deconvolution microscopy, which revealed translocation of β-
catenin to the nucleus that could be inhibited by PD0325901 (c) (shown: one 
hour following SCF/FBS stimulation). E1-KO and E2-KO mast cells demonstrated 
deregulated β-catenin levels, even under basal conditions (c). This immunoblot is 
representative of several different experiments, although the level of β-catenin 
deregulation varied widely at non-stimulated conditions in E1-KO and E2-KO 
mast cells. By contrast, β-catenin levels were consistently negligible in non-
stimulated WT cells.  
189 
Erk1/2 disruption in primary mature mast cells.  
We have developed a foamy/lentiviral gene delivery system to create DKO 
mast cells while bypassing the requirement for Erk in myeloid precursor 
proliferation and mast cell cytopoiesis. This integrating retrovirus delivers a 
previously described Cre:eGFP fusion construct (184) placed under control of the 
splenic-focus forming virus promoter (SFFV), which potently drives transcription 
in eukaryotic cells. We generated this Cre:eGFP delivery system in conjunction 
with our collaborator Helmut Hannenberg, who had previously constructed 
proprietary elements within the viral, polymerase, and foamyviral envelop 
plasmids (185, 186)(Figure 36a).  
Through this three-plasmid, 293T-based packaging system (modified from 
protocols described previously (187-189)), we have achieved titers at 109 to 1010 
virions/mL, allowing us to achieve up to 70% transduction efficiency in mast cells, 
as measured by eGFP-positivity on flow cytometry. Importantly, we did not 
observe virus-induced toxicity, even at 103 virions per mast cell (we have 
routinely used 25-50 virions/cell). In our initial experiment, we found clear 
evidence that delivery of Cre:eGFP to the genome of primary mature mast cells 
can successfully excise floxed alleles (Figure 36b). In ongoing experiments, we 
are using FACS to sort GFP+ cells prior to analysis, thus ensuring putatively pure 
populations of Erk2-excised mast cells. The immunoblot in 36b shows antibody 
detection of protein isolated from an unsorted cell population and therefore 
underrepresents the efficiency of the Cre in excising the Erk2 allele. 
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To date, we are unaware of any study demonstrating foamy/lentiviral 
transduction of primary murine mast cells, although one study achieved lentiviral 
transduction in human mast cells (190) while another reported adenoviral 
transduction in rodent mast cells (191). This tool and protocol should prove 
useful for future studies in primary cultured mast cells. Moreover, our initial data 
have recapitulated aspects of the PD0325901 data, showing that Erk1-/-Erk2flox/flox 
cells transduced with Cre:eGFP (effectively, DKO) diminish to near zero over 
time (Figure 36c), suggesting a primarily proliferative defect in DKO mast cells. 
We did not observed rapid loss of or increased apoptosis in this population, 
suggesting that Erk disruption does not preclude mast cell survival in tissue 
culture. 
We are currently repeating deconvolution microscopy experiments, the 
multiplex assays, and our hemcytometer-, thymidine-, and BrdU-based 
proliferation studies on Cre:eGFP transduced mast cells, seeking to refine our 
PD0325901-based results. Based on our immunoblot data, we hypothesize that 
although DKO mast cells will not proliferate, they may demonstrate enhanced 
survival secondary to compensatory deregulation in PI-3K-Akt pathways. 
Potentially, DKO cells will demonstrate an ability to enter S-phase or to complete 
mitosis, providing genetic granularity as to the functions of Erk1/2 in this specific 
cell and receptor-ligand system.  
Figure 36a 
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Figure 36: Efficient transduction of primary mast cells with a Cre:eGFP 
carrying lentivirus. Using standard cloning techniques, we inserted a Cre:eGFP 
fusion gene downstream of the SFFV promoter in a lentivirus encoding plasmid 
(a). To generate virus, we co-transfected 293T cells with pcl7CREeGFP, a 
plasmid encoding a foamyviral envelope, and a plasmid encoding viral 
polymerases. Transduced mast cells carrying the Erk2flox/flox allele demonstrated 
reduction in Erk2 protein, which was more notable in E2-KO samples as 
compared to DKO samples (b) (immunoblot was performed on unsorted mast 
cells following transduction, and some Erk2 signal is expected). Four week old 
mast cells were transduced with pcl7CREeGFP, and after four weeks of culture 
in IL-3, the putative DKO population (Erk1-/-Erk2flox/flox cells that were Cre:eGFP+) 
disappeared (c).  
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PD0325901 reduces mast cell infiltration in NF1-associated tumors. 
Based on our findings of a critical requirement for Erk in mast cell 
cytopoiesis and SCF-stimulated proliferation, we hypothesized that PD0325901 
would dampen mast cell invasion associated with tumorigenesis and 
maintenance in the Nf1flox/-; PeriostinCre+ tumor model. These mice harbor 
biallelic inactivation of Nf1 in Schwann cell precursors and Nf1+/- supporting 
tissues, including the hematopoietic system (24, 82, 83, 86). As Yang et al have 
previously shown, Nf1+/- bone marrow accelerates tumor formation and 
progression in these mice, as compared to tumor mice transplanted with WT 
bone marrow (24). Although we had initially intended to transplant these mice 
with Nf1+/-Erk1-/-Erk2flox/flox hematopoietic stem cells, our prior studies suggested 
that DKO HSCs would fail to sustain hematopoiesis or generate mast cells and 
therefore preclude our ability to genetically study the consequence of dual Erk 
disruption on plexiform neurofibroma formation and maintenance. 
We initiated the PD0325901 study in mice containing validated plexiform 
neurofibromas, as assessed by PET-CT using  [18F] fluorodeoxyglucose (FDG). 
Five tumor model mice were fed by oral gavage every day for six weeks with 
12.5 mg/kg PD0325901. After the six-week treatment, the mice were killed and 
assessed. We found that this dose of PD0325901 moderately reduced the 
numbers of mast cells infiltrating the dorsal root ganglia of Nf1flox/-; PeriostinCre+ 
mice (Figure 37). However, we did not find a reduction in tumor size during the 
course of this treatment.  
Figure 37 
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Figure 37: PD0325901 reduces mast cell infiltration in a neurofibroma 
tumor model. Nf1flox/-; PeriostinCre+ tumor model mice with validated tumors 
were fed by oral gavage every day for six weeks with 12.5 mg/kg PD0325901 
dissolved in 0.5% hydroxypropyl methylcellulose/0.2% Tween-80. After the six-
week treatment, the mice were killed and their tissues assessed by histology. 
PD0325901 reduced mast cell infiltration to the hyperplastic dorsal root ganglia, 
as shown by quantification of mast cells per high powered field (n=5, *p<0.01, 
student’s unpaired t-test).  
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DISCUSSION 
The plexiform neurofibromas and myeloid leukemia that develop in 
individuals with Neurofibromatosis type 1 have no medical treatment. Both 
conditions create substantial morbidity and increase mortality. Specifically, nerve-
impinging plexiform neurofibromas can compromise bowel and bladder 
dysfunction, cause sleeplessness and anorexia, and compress vital structures 
such as the airway, leading to suffering and death. JMML, by comparison, 
causes bone marrow failure and is universally fatal. Given these grim outlooks for 
the NF1 patient, we stress an emergent need for molecularly-targeted 
compounds in the management of NF1-associated tumors and leukemia.  
Previous studies have shown that hyperactive Mek-Erk signaling in the 
hematopoietic compartment contributes to leukemic cell outgrowth as well as to 
the aberrant mast cell activity promoting the inflammatory microenvironment that 
underpins plexiform neurofibroma genesis and maintenance. Importantly, several 
studies have shown that Nf1 deficient mast cells and myeloid progenitor cells 
demonstrate increased levels of phosphorylated Erk1/2 in response to multiple 
ligands, including SCF, a principal factor discussed throughout these studies.  
Despite these correlative studies, little is known about the differential and 
combined roles of Erk1 and Erk2 in controlling SCF-mediated function in normal 
and diseased hematopoietic stem cells, myeloid progenitors, and mature mast 
cells. All prior studies in these cell types have relied on chemical Mek-Erk 
inhibition, principally in tissue culture and with the use of older generation agents 
(e.g. U0126, PD98059). Likewise, no report has heretofore explored Erk1 and 
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Erk2’s contribution to stable, long-term hematopoiesis. While we performed these 
studies with an end goal of unraveling new treatments for NF1-associated 
disease, we focused our experiments on foundational experiments exploring 
Erk1 and Erk2 in hematopoiesis, myelopoiesis, and mast cell cytopoiesis and 
function. While these processes are prone to dysfunction in patients with genetic 
alterations of the NF1 gene, they are also critical to host defense, blood 
generation, and homeostasis in many organisms. A better understanding of Erk1 
and Erk2 in hematopoiesis not only informs the management of NF1-associated 
diseases, but is also informs fundamental physiological processes.  
Our data overwhelmingly indicate that hematopoiesis and myelopoiesis 
require at least one isoform of Erk. Moreover, our genetic studies of mast cell 
cytopoiesis, our chemical-based experiments in mature mast cells, and our initial 
DKO genetic studies in primary cultured mast cells indicate a similar requirement 
for one isoform of Erk in SCF- and IL-3 mediated mast cell function. Intriguingly, 
our experiments indicate a broad dispensability for single Erk isoforms in 
hematopoiesis and SCF-mediated mast cell proliferation, although we resist a 
conclusion that these individual isoforms universally have no function in the 
presence of the other. Indeed, our own studies in osteoclasts have revealed that 
Erk1 critically contributes to multiple M-CSF-mediated osteoclast functions, 
including aberrant bone mineralization in animals transplanted long-term with E1-
KO hematopoietic stem cells. Thus, our study reveals broad requirements for one 
isoform of Erk in hematopoiesis, but it does not preclude roles for Erk1 or Erk2 in 
specific cell lineages controlled by distinct ligand-receptor systems. 
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Erk and hematopoiesis  
As shown here, Erk signaling critically contributes to long-term 
hematopoietic maintenance. As Erk1/2 activity appears to regulate cell 
differentiation, survival, and the G1/S transition in multiple primary cells and cell 
lines (114, 119, 121, 133, 192-197), we had generated at least three initial 
hypotheses as to the consequence of dual Erk1/2 disruption in the hematopoietic 
system.  
First, we hypothesized that DKO HSC frequency would expand relative to 
total marrow cellularity, representing a differentiation block, whereby HSCs could 
proliferate but not give rise to committed progeny. Because HSCs have a much 
lower proliferative index than their committed progeny (149, 150, 198), total bone 
marrow cellularity would still decrease and HSC number and frequency would 
increase. However, we found no evidence of increased HSC frequency in DKO 
bone marrow. Even so, we did find a mildly increased percentage of “lineage 
negative” and CD150+CD48/41- cells, implying that at least some aspects of cell 
surface protein expression and perhaps differentiation require Erk. Specifically, 
Erk disruption abrogated the expression of c-kit on bone marrow cells, although it 
is difficult to conclude that this represents a differentiation block versus a primary 
proliferative deficiency (as exponentially expanding myeloid progenitors are c-kit-
expressing). We also point to our colony forming assays, where DKO cells 
showed no colony formation capacity – in the case of a differentiation block, one 
would expect the rapid outgrowth of primitive, undifferentiated cells on highly 
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enriched media. In short, while we cannot rule out a differentiation block in Erk-
disrupted HSCs, our data suggest  preponderant defects in proliferation. 
Second, we hypothesized that DKO HSCs would rapidly undergo 
apoptosis, leading to a decreased frequency of HSCs, hematopoietic collapse, 
anemia, and death. While all primary DKO animals died during or shortly after the 
polyIC regimen, we did not observe the catastrophic lethality seen in other 
apoptosis-inducing deletions (e.g. Mx1Cre+Cul4aflox/flox mice, (199-201)). 
Moreover, we did not find substantial evidence of increased apoptosis in DKO 
spleen cells or bone marrow cells, and the DKO HSC frequency was not 
reduced. However, apoptosis can be difficult to detect in vivo, and we would 
expect cycle-arrested cells to eventually undergo cell death. Thus, increased 
apoptosis may be a reasonable consequence of failed proliferation, although we 
did not detect this phenomenon.  
We also hypothesized that Erk disrupted HSCs would demonstrate an 
inability to synthesize DNA, as suggested by other studies arguing for Erk as the 
“master regulator” of the G1/S transition (reviewed in (114)). Surprisingly, though, 
we found that DKO HSCs incorporated BrdU and had increased nuclear material, 
even when assessed at different time points following the polyIC regimen. We 
considered that these BrdU+ and Pyronin Y/Hst positive HSCs may represent 
non-recombined cells rapidly proliferating to compensate for the loss of true DKO 
HSCs, but individually sorted HSCs failed to expand in culture. Likewise, few if 
any colonies formed when plating tens of thousands of bone marrow cells which 
would hypothetically contain equivalent numbers of HSCs to WT samples. These 
202 
data suggest to us a proliferative defect in DKO HSCs at a cell cycle stage 
beyond the G1/S transition.  
Despite the mass of tissue culture data suggesting a primary role for Erk 
in the G1/S transition, our observations in the DKO HSC are not without 
precedence. Indeed, Erk can localize to kinetochores, spindle poles, and the 
midbody, leading others to hypothesize that Erk plays important roles in G2 and 
mitosis (202, 203). Moreover, Erk1/2 knockdown in engrafted epidermal 
keratinocytes induces G2/M arrest while knockdown in fibroblasts induces G1/S 
arrest, arguing that in certain cell types the G1/S transition does not depend upon 
Erk (115). Accordingly, Erk functions may vary by cell type, and established cell 
culture findings may not directly predict in vivo physiology.  
Of note, our studies rely on genetic inhibition in vivo while most prior 
studies have relied on chemical inhibition or overexpression in vitro, secondary to 
stimulation by a defined growth factor. As such, Erk’s modulation of the cell cycle 
could depend on a combination of structural interactions, kinase activities, and 
pathways initiated by multiple cytokines and growth factors. Future studies in the 
hematopoietic system could attempt to elucidate these mechanisms via 
restoration of transplanted HSCs with kinase-dead and other Erk variants prior to 
Cre induction. Although we are uncertain if these intricacies would directly 
elucidate our work with experimental therapies for NF1-associated disease, we 
postulate that increased mechanistic understanding will facilitate the 
development of targeted combinatorial therapies in the future. For example, 
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diseased HSCs could be induced to undergo cell cycle arrest and subsequently 
brought to apoptosis with a different, cycle stage-specific agent. 
In addition to unraveling a novel proliferative consequence for Erk 
disruption in hematopoietic stem cells, our study critically complements a handful 
of other in vivo hematopoietic studies which, taken in isolation, may obfuscate 
the critical role for Erk pan-hematopoiesis. In the single previous assessment of 
dual Erk1/2 disruption using Mx1Cre, Yasuda et al reported defects in only pre-B 
cell expansion due to loss of Erk-dependent CREB and Elk1 activities (105). 
They did not assess myelopoiesis, long-term hematopoiesis, or HSC 
proliferation. Likewise, two other reports have shown that mice disrupted for 
Erk1/2 in T cells (pLck-cre and Cd4-Cre) have greatly diminished T cell 
production and function (104, 204). Aggregating these findings with our findings, 
we have concluded that HSC proliferation and physiological hematopoiesis 
requires at least one Erk isoform.  
Similarly, our study refines recent, conflicting conclusions derived from the 
use of Mek-Erk chemical inhibitors in tissue culture (reviewed in (109)). Mek 
inhibitors PD98059 and U0126 are used at micromolar concentrations, are prone 
to crystallization, and have potential off-target effects. Relying on these inhibitors, 
two reports have argued that Mek-Erk promotes monocyte generation while 
suppressing granulocytopoiesis via C/EBPα (107, 108). Contrastingly, Geest et al 
showed that that Mek-Erk activity controls granulocyte production from CD34+ 
cells (106). And, Hsu et al suggested that Erk regulates GM colony formation 
from HSCs/MPPs but not from CMPs, thus implying Erk dispensability in later 
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precursors (110) while also arguing that Erk negatively regulates B cell 
production. However, our study and Yasuda et al have genetically shown that Erk 
positively regulates B cell production, and our colony forming assays 
demonstrate that DKO bone marrow cells (which contain phenotypically-
confirmed MPPs, CMPs, GMPs, and MEPs) have little to no colony potential. 
Thus, our genetic data elucidate Erk1/2’s importance in HSC proliferation, pan-
myeloid colony formation, and stable hematopoiesis while obviating aspects of 
previous studies relying on chemical inhibitors in tissue culture. 
Single Erk isoforms appear dispensable for hematopoietic stability, an 
important observation vis-à-vis recent debate over putative isoform-specific 
functions. For example, Erk1 negatively regulates splenic erythropoiesis (179) 
and fibroblast proliferation (128) while Erk2 positively regulates proliferation, 
survival, and differentiation in various cell types (116, 121). However, genetic 
studies in fibroblasts have shown both isoforms to positively contribute to 
proliferation, in a gene dose-dependent and isoform-independent manner (132, 
133). Enhanced proliferation in some Erk1-disrupted cells, then, may result solely 
from Erk2 over-compensation (i.e. not from intrinsic negative-regulator 
properties). Although we detected no critical disparities between WT, E1-KO, and 
E2-KO hematopoietic stability, we observed reduced peripheral T cells in E2-KO 
HSC transplanted mice, recapitulating data from the previous studies using 
lymphocyte-specific Cre promoters (104, 204). We also examined E1+/-E2-KO 
specimens, again finding no difference in marrow cellularity or colony formation.  
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Thus, we assert that each Erk isoform permits HSC proliferation and 
myelopoiesis in a binary fashion but that HSC BrdU incorporation and, 
potentially, S-phase entry, do not require Erk. While single isoforms appear 
dispensable for stable, long-term hematopoiesis, we have confirmed that Erk2 
modulates T cell survival (following Fisher et al), and we have found that specific 
myeloid effector cells (e.g. osteoclasts) may demonstrate differential loss- or 
gain-of-function phenotypes secondary to Erk1 and/or Erk2 disruption. We 
reiterate that the conclusions regarding Erk function based on chemical inhibition 
in various cell culture systems may unnecessarily convolute our observation of a 
broad requirement for Erk in hematopoietic stem cell proliferation and 
myelopoiesis. 
Taken together, our findings suggest that pharmacological Mek-Erk 
inhibition may be a powerful technique to modulate aspects of normal and 
diseased hematopoiesis. While we are principally interested in the treatment of 
NF1-associated leukemia and tumors, we also view the Ras-Raf-Mek-Erk axis as 
a critical ramifying junction in the control of normal hematopoiesis. Potentially, 
temporary pharmacological Mek-Erk inhibition will permit advanced, non-
deleterious manipulation of the hematopoietic system.  
As a potential example, recent studies have shown that treatment of mice 
with ACK2, an antibody directed against the c-kit antibody, induces 
hematopoietic stem cells to leave the bone marrow and enter the peripheral 
blood, allowing for a non-myeloablative HSC transplantation during this “window” 
period (205, 206). Such insights could allow medical practitioners to seamlessly 
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replace a diseased hematopoietic system while avoiding the morbidities 
associated with lethal irradiation and myeloablative chemotherapy. Because 
PD0325901 targets a critical node in the c-kit pathway, the use of this drug alone 
or in combination with niche clearing antibodies may accelerate egress, thus 
refining techniques of non-myeloablative transplantation (which are, as yet, in 
preclinical stages). We do not currently have data suggesting that Erk disruption 
induces niche clearance, and our genetic studies do not temporally fall within the 
“window” of mobilization, which typically occurs just a few days after HSC 
suppression. However, we anticipate discoveries to be made during 
hematopoietic studies of mice receiving systemic PD0325901 or other Mek-Erk 
inhibitors. 
Finally, we view Mek-Erk pharmacological inhibition as a potentially crucial 
tool for modulating the course of NF1-associated JMML and other leukemia. As 
preliminary evidence, mice developing a virally-transformed, Nf1-/- leukemia lived 
three times as long when treated with PD0325901, although the mice still 
succumbed to their disease, putatively through cooperating mutations in genes 
encoding proteins within other pathways (157). Similarly, PD0325901 
successfully treated mice harboring a myeloproliferative disease induced by an 
oncogenic Ras construct (158). Despite these promising studies, it remains 
unknown whether leukemic cell outgrowth can occur in the genetic absence of 
Erk1 and Erk2. To test this, we have initiated a long-term hematopoietic stem cell 
transplantation study assessing simultaneous Nf1, Erk1, and Erk2 deletion, as 
shown in Figure 24. While we do not expect the results of this study to 
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immediately inform the treatment of NF1-associated leukemia – especially given 
our finding that normal hematopoiesis requires Erk – we expect to resolve the 
question as to whether more efficient and targeted Mek-Erk inhibitors can 
theoretically abolish hematopoiesis in both normal and diseased cells, regardless 
of cooperating mutations outside of the Erk1 or Erk2 locus.  
Mast cells and future directions 
In mouse models of plexiform neurofibroma formation, aberrant mast cell 
activity secondary to SCF-stimulation underpins tumor formation and 
maintenance. Multiple studies have shown that SCF-stimulated Nf1+/- mast cells 
have increased potency and latency in phospho-Erk1/2 signaling (reviewed in 
(82, 83)). However, the specific roles for Erk1 and Erk2 in the SCF-stimulated 
mast cell have not previously been examined genetically. In fact, functional 
studies of Erk activity have, as yet, relied on the older generation Mek-Erk 
inhibitor PD98059.  
Here, we show that while Erk1 and Erk2 are largely dispensable for SCF-
stimulated mast cell proliferation and cytokine synthesis, the Mek-Erk inhibitor 
PD0325901 efficiently prevents SCF-mediated mast cell proliferation at sub-
micromolar concentrations. Throughout the course of our study, PD0325901 
proved to be a potent, efficacious, stable, and highly-selective inhibitor of Mek-
Erk activation. Accordingly, this molecule should serve as a valuable tool in the 
continued elaboration of Erk1/2 kinase functions in mast cells, especially as a 
complement to our ongoing development of genetic models. PD0325901 also 
has high oral bioavailability, making it an attractive candidate for clinical use. In 
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our mouse-based study of plexiform neurofibroma formation, PD0325901 
treatment reduced mast cell infiltration to tumor tissue. 
However, at the tested dosing schedule, PD0325901 did not reduce tumor 
burden. We first considered that our tested dose was not sufficient, as we were 
well below the toxic threshold (50-100 mg/kg) recorded in rodents (113). 
Additionally, we based our dosing schedule on a prior publication assessing 
PD0325901efficacy in inhibiting the growth of NF1-associated AML, but these 
transformed cells demonstrated an exquisite sensitivity to Mek-Erk inhibition, with 
a 10 to 100 fold lower IC50 for colony formation, as compared to normal bone 
marrow cells (157). Because neurofibroma-associated mast cells, including Nf1+/- 
mast cells, are not oncogenically transformed, the suppression of mast cell 
cytopoiesis in the hematopoietic system may require much higher circulating 
plasma levels of PD0325901. 
However, based on our findings of a broad and critical requirement for 
Mek-Erk signaling in normal myelopoiesis, we have considered other 
consequences of high dose PD0325901 on hematopoietic stem cell and myeloid 
progenitor cell maintenance. As discussed above, our findings justify additional, 
foundational studies of myelopoiesis and in vivo mast cell function in the of 
PD0325901 treatment. To establish an effective PD0325901 dose for abrogating 
SCF-mediated mast cell cytopoiesis and recruitment to local tissue, we are 
implanting micro-osmotic pumps loaded with SCF into the subcutaneous tissue 
of WT mice, cohorts of which will receive increasing concentrations of 
PD0325901 by oral gavage. These findings should directly inform PD0325901’s 
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efficacy in modulating mast cell pathophysiology in NF1-associated tumors, as 
deregulated Schwann cells similarly recruit mast cells to local tissues through 
secreted SCF. 
Alternatively, PD0325901’s potentiation of SCF-mediated cytokine 
production may lead to increased local inflammation. This increased biological 
activity could override the possible benefit of decreased mast cell numbers in 
tumor tissue. PD0325901 largely increased the level of cytokines found in the 
conditioned media of SCF-stimulated mast cells, including several factors known 
to recruit and activate macrophages (e.g. MIP, MCP). Hypothetically, activated 
macrophages can drive tumor vascularization, increase extracellular matrix 
remodeling and deposition, and further promote inflammatory 
microenvironments. These initial observations are challenging, and further 
studies will be required to weigh the benefits of mast cell number reduction 
against the possible short-term induction of cytokine synthesis and secretion.  
The observation of increased cytokine production in PD0325901-treated 
mast cells also poses several mechanistic questions. We have postulated that 
PD0325901 potentiates cytokine synthesis through upregulation of PI-3K-
dependent pathways, as a recent study has indicated a specific role for PI-3K-Akt 
signaling in the production of MCP-1 (207). Likewise, multiple studies have 
broadly implicated PI-3K in the modulation of IgE- and SCF-mediated cytokine 
production and release (208). In our biochemical studies, PD0325901-inhibited 
mast cells consistently demonstrated increased levels of phospho-Akt after four 
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to six hours of SCF stimulation, providing a temporal and mechanistic correlation 
to our observation of increased cytokine production in PD0325901-treated cells. 
Hypothetically, translational level compensation for suppressed Mek-Erk 
signaling could increase activity in PI-3K-depedendent pathways. Several studies 
have shown that a decreased level of the mTOR-dependent protein IRS-1 leads 
to increased activation of PI-3K-Akt, a biochemical phenomenon which has 
plagued the clinical efficacy of mTOR inhibitors (e.g. Rapamycin) due to 
unintended Akt-mediated cellular mitogenesis (209). In our current line of inquiry, 
we are asking whether the loss of Mek-Erk activity reduces mTOR-mediated 
production of IRS-1, as Mek1/2-Erk1/2 have been shown to crosstalk with and 
potentiate the mTOR pathway (210). This reduction of IRS-1 could then disinhibit 
PI-3K-Akt signals and subsequent cytokine production if, indeed, cytokines 
primarily depend upon Akt-mediated signals. 
To accomplish these goals, we are employing a variety of chemical and 
genetic approaches to further study SCF-stimulated primary cultured mast cells. 
As an example, we are assessing the effect of various inhibitors and genetic 
conditions on the level of the mRNAs encoding our identified cytokines. These 
experiments should not only elucidate the transcriptional level mechanism of 
control for cytokine production, but they will also ensure that PD0325901 does 
not simply potentiate cytokine levels through direct or indirect inhibition of 
secreted proteases. 
We also observed mildly increased levels of phospho-AktS473 and 
phospho-GSK3βS9 as well as deregulated total β-catenin levels in E1-KO and E2-
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KO mast cells. These compensations within canonical and non-canonical PI-3K 
pathways may help normalize SCF-mediated mast cell function in the context of 
single Erk isoform disruption. Of note, E1-KO and E2-KO mast cells, while no 
different from WT in their SCF-mediated proliferative capacity, tended to produce 
more cytokine, although a larger sample size needs to be evaluated. These 
observations preliminarily reinforce the hypothesis that deregulated Akt signaling 
influences cytokine production. 
Notwithstanding the deregulation of β-catenin signaling in E1-KO and E2-
KO mast cells, the simple observation of SCF-induced β-catenin activity and 
translocation is a novel finding. As of May 2011, a PubMed search for “mast” and 
“catenin” reveals one relevant publication: an observation of SCF-stimulated β-
catenin translocation in a mast cell leukemia line with the implication made that 
β-catenin activity here is correlated with oncogenesis (182). To our knowledge, 
no study has characterized β-catenin signaling in primary or untransformed mast 
cell physiology. 
 Intriguingly, recent investigations have unraveled intimate relationships 
between MAPK pathways and β-catenin. For example, Rac1-JNK signaling 
shuttles β-catenin to the nucleus during canonical Wnt signaling (180), and 
Erk1/2 can influence β-catenin levels through its phosphorylation of GSK3β 
(181). In the latter case, Erk physically interacts with GSK3β at a docking motif, 
phosphorylates it at threonine 43, and activates p90rsk, which then 
phosphorylates GSK3β at serine 9 in a manner dependent on threonine 43 
phosphorylation. Phosphorylated GSK3β disassociates from β-catenin, which 
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ceases its sequestration and degradation, allowing for its upregulation, 
phosphorylation, and translocation to the nucleus. 
Following these observations, PD0325901 treatment of SCF-stimulated 
mast cells diminished the upregulation of β-catenin levels and prevented its 
nuclear translocation. Hypothetically, then, single Erk isoform disruption results in 
Akt hyperactivation and increased activity in Akt-GSK3β-β-catenin signaling, but 
the short-term silencing of Mek-Erk kinase activity abrogates this axis by 
preventing needed co-activating signals, such as phosphorylation of GSK3β at 
threonine 43. Our laboratory intends to elucidate this pathway genetically in 
CRE:eGFP lentivirus-treated DKO mast cells and in mast cells cultured from the 
bone marrow of Mx1Cre+Ctnnb1flox/flox (β-catenin conditional knockout) mice. In 
all, we aim to assess the functional and biochemical aspects of β-catenin 
signaling in the mast cell, especially as it relates to signaling events in 
established c-kit-dependent pathways. 
Finally, as with our hematopoietic studies, we found few differences in the 
proliferative kinetics between SCF-stimulated WT, E1-KO, and E2-KO mast cells. 
Our proliferation studies included thymidine incorporation assays, hemcytometer-
based assays, and assays of total metabolic ability (e.g. MTT). In all of these 
experiments, shown and not shown, we rarely detected differences in the single 
Erk KOs, and when we did, the differences were unremarkable. By contrast, 100 
nM PD0325901 efficiently inhibited total proliferative output and reduced 
thymidine and BrdU incorporation by about one-half. We did not detect an 
additional effect of PD0325901 in preventing completion of the cell cycle after S-
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phase entry. We wonder how 100 nM PD0325901completely inhibited total 
proliferative output but reduced BrdU and thymidine incorporation by only about 
50%. These data suggest that Erk’s modulation of mast cell proliferation is not 
limited to DNA synthesis, as we had observed in DKO HSCs. Multiple putative 
explanations exist, including potential anti-proliferative or pro-apoptotic 
consequences of PD0325901-induced cytokine release. In short, more genetic 
studies of the elusive DKO mast cell are needed.  
Conclusions 
Prior to initiating our study of Erk-disrupted hematopoietic stem cells, we 
were surprised to be unable to generate DKO mast cells in tissue culture. In fact, 
this dramatic phenotype instigated our hematopoietic stem cell experiments. 
Multiple studies of SCF-stimulated mast cells have suggested that PI-3K-
mediated pathways play the preponderant role in modulating mast cell 
cytopoiesis, proliferation, and migration (87, 96, 98, 101, 211-213). In the reports 
implicating Erk1/2 as a proliferative factor, SCF-stimulated mast cells required up 
to 50 μM of PD98059 to prevent proliferation, suggesting that signals in addition 
to the Ras-Raf-Mek-Erk cascade could contribute to cell cycle proliferation. 
Additionally, prior hematopoietic studies in tissue culture had implied that that 
Erk1/2 was dispensable in certain stages of myelopoiesis. Taken together, we 
labored under the assumption that DKO myeloid progenitors could give rise to 
DKO mast cells. Accordingly, we expected to test Nf1+/-DKO mast cell function, 
biochemistry, and modulation of plexiform neurofibroma formation. 
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However, our colony assays and liquid culture experiments all indicated 
that mast cells could not be generated without one isoform of Erk. Based on 
these findings, we extended our investigation into the hematopoietic stem cell, 
performing long-term competitive transplantation studies to assess Erk-
dependent hematopoiesis. Here, we found that the generation of nearly all 
myeloid cells requires one isoform of Erk, secondary to proliferative failure in the 
hematopoietic stem cell. Combined with other observations made in Erk-deficient 
B cells and T cells, we concluded that physiological hematopoiesis requires Erk. 
These insights may inform finessed modulation of normal hematopoiesis 
and diseased bone marrow. Specifically, we are interested in silencing Mek-Erk 
activity in the treatment of NF1-associated plexiform neurofibromas, a strategy 
which we would hypothesize to succeed primarily through the dampening of an 
abnormally functioning hematopoietic system. However, our initial findings 
regarding potentiated cytokine synthesis have breathed an air of caution on this 
optimism. Notwithstanding, we also anticipate Mek-Erk inhibition as a suitable 
strategy for controlling NF1-associated leukemia, but the proliferative 
requirement for Mek-Erk activity in Nf1-deficient myeloid cells remains unknown.  
Our data demonstrate that Erk1 and Erk2 constitute a crucial ramifying 
nexus for the transduction of cellular proliferative signals through multiple 
hematopoietic ligand-receptor systems. This nexus is so crucial, in fact, that the 
function of an individually-disrupted Erk isoform can typically be subsumed by its 
remaining complement, albeit with possible alterations in other biochemical 
pathways. These insights elucidate the importance of Erk signaling in myeloid 
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and hematopoietic stem cell biology and provide foundational evidence for 
potential uses of pharmacological Mek-Erk inhibitory agents. Our study ends with 
a note of caution, too, hinting that Mek-Erk inhibition may be a double-edged 
sword, thus imploring the need for further experimentation in mouse models of 
normal and diseased hematopoiesis.  
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